1
|
Haase R, Pinetz T, Kobler E, Bendella Z, Gronemann C, Paech D, Radbruch A, Effland A, Deike K. Artificial T1-Weighted Postcontrast Brain MRI: A Deep Learning Method for Contrast Signal Extraction. Invest Radiol 2024:00004424-990000000-00240. [PMID: 39074258 DOI: 10.1097/rli.0000000000001107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/31/2024]
Abstract
OBJECTIVES Reducing gadolinium-based contrast agents to lower costs, the environmental impact of gadolinium-containing wastewater, and patient exposure is still an unresolved issue. Published methods have never been compared. The purpose of this study was to compare the performance of 2 reimplemented state-of-the-art deep learning methods (settings A and B) and a proposed method for contrast signal extraction (setting C) to synthesize artificial T1-weighted full-dose images from corresponding noncontrast and low-dose images. MATERIALS AND METHODS In this prospective study, 213 participants received magnetic resonance imaging of the brain between August and October 2021 including low-dose (0.02 mmol/kg) and full-dose images (0.1 mmol/kg). Fifty participants were randomly set aside as test set before training (mean age ± SD, 52.6 ± 15.3 years; 30 men). Artificial and true full-dose images were compared using a reader-based study. Two readers noted all false-positive lesions and scored the overall interchangeability in regard to the clinical conclusion. Using a 5-point Likert scale (0 being the worst), they scored the contrast enhancement of each lesion and its conformity to the respective reference in the true image. RESULTS The average counts of false-positives per participant were 0.33 ± 0.93, 0.07 ± 0.33, and 0.05 ± 0.22 for settings A-C, respectively. Setting C showed a significantly higher proportion of scans scored as fully or mostly interchangeable (70/100) than settings A (40/100, P < 0.001) and B (57/100, P < 0.001), and generated the smallest mean enhancement reduction of scored lesions (-0.50 ± 0.55) compared with the true images (setting A: -1.10 ± 0.98; setting B: -0.91 ± 0.67, both P < 0.001). The average scores of conformity of the lesion were 1.75 ± 1.07, 2.19 ± 1.04, and 2.48 ± 0.91 for settings A-C, respectively, with significant differences among all settings (all P < 0.001). CONCLUSIONS The proposed method for contrast signal extraction showed significant improvements in synthesizing postcontrast images. A relevant proportion of images showing inadequate interchangeability with the reference remains at this dosage.
Collapse
Affiliation(s)
- Robert Haase
- From the Clinic of Neuroradiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany (R.H., E.K., Z.B., C.G., D.P., A.R., K.D.); Institute of Applied Mathematics, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany (T.P., A.E.); Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (D.P.); and German Center for Neurodegenerative Diseases (DZNE), Helmholtz Association of German Research Centers, Bonn, Germany (A.R., K.D.)
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Richter H, Koke A, Soschinski PN, Martin LF, Bücker P, Sperling M, Karst U, Radbruch A, Witten A, Jeibmann A. Elemental bioimaging and transcriptomics reveal unchanged gene expression in mouse cerebellum following a single injection of Gadolinium-based contrast agents. Sci Rep 2023; 13:6844. [PMID: 37100846 PMCID: PMC10133442 DOI: 10.1038/s41598-023-33066-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Accepted: 04/06/2023] [Indexed: 04/28/2023] Open
Abstract
Gadolinium (Gd) deposition in the brain, first and foremost in the dentate nucleus in the cerebellum, following contrast enhanced MRI, rose awareness of potential adverse effects of gadolinium-based contrast agent (GBCA) administration. According to previous in vitro experiments, a conceivable side-effect of Gd deposition could be an alteration of gene expression. In the current study, we aimed to investigate the influence of GBCA administration on gene expression in the cerebellum of mice using a combination of elemental bioimaging and transcriptomics. In this prospective animal study, three groups of eight mice each were intravenously injected with either linear GBCA gadodiamide, macrocyclic GBCA gadoterate (1 mmol GBCA/kg body weight) or saline (NaCl 0.9%). Animals were euthanized four weeks after injection. Subsequently, Gd quantification via laser ablation-ICP-MS and whole genome gene expression analysis of the cerebellum were performed. Four weeks after single application of GBCAs to 24-31 days old female mice, traces of Gd were detectable in the cerebellum for both, the linear and macrocyclic group. Subsequent transcriptome analysis by RNA sequencing using principal component analysis did not reveal treatment-related clustering. Also differential expression analysis did not reveal any significantly differentially expressed genes between treatments.
Collapse
Affiliation(s)
- Henning Richter
- Diagnostic Imaging Research Unit, (DIRU), Clinic for Diagnostic Imaging, Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zurich, Winterthurerstraße 258C, 8057, Zurich, Switzerland.
| | - Anke Koke
- Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149, Münster, Germany
| | - Patrick N Soschinski
- Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149, Münster, Germany
| | - Louise F Martin
- Institute of Laboratory Animal Science, Vetsuisse Faculty, University of Zurich, Winterthurerstraße 260, 8057, Zurich, Switzerland
| | - Patrick Bücker
- Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstraße 30, 48149, Münster, Germany
| | - Michael Sperling
- Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstraße 30, 48149, Münster, Germany
| | - Uwe Karst
- Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstraße 30, 48149, Münster, Germany
| | - Alexander Radbruch
- Clinic of Neuroradiology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany
| | - Anika Witten
- Core Facility Genomics, Medical Faculty, University of Münster, Domagkstrasse 3, 48149, Münster, Germany
| | - Astrid Jeibmann
- Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149, Münster, Germany
| |
Collapse
|
3
|
Hua N, Minaeva O, Lupoli N, Franz ES, Liu X, Moncaster JA, Babcock KJ, Jara H, Tripodis Y, Guermazi A, Soto JA, Anderson SW, Goldstein LE. Gadolinium Deposition in the Rat Brain Measured with Quantitative MRI versus Elemental Mass Spectrometry. Radiology 2023; 306:244-251. [PMID: 36125373 PMCID: PMC9792715 DOI: 10.1148/radiol.212171] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 06/08/2022] [Accepted: 07/15/2022] [Indexed: 01/19/2023]
Abstract
Background T1-weighted MRI and quantitative longitudinal relaxation rate (R1) mapping have been used to evaluate gadolinium retention in the brain after gadolinium-based contrast agent (GBCA) administration. Whether MRI measures accurately reflect gadolinium regional distribution and concentration in the brain remains unclear. Purpose To compare gadolinium retention in rat forebrain measured with in vivo quantitative MRI R1 and ex vivo laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) mapping after gadobenate, gadopentetate, gadodiamide, or gadobutrol administration. Materials and Methods Adult female Sprague-Dawley rats were randomly assigned to one of five groups (eight per group) and administered gadobenate, gadopentetate, gadodiamide, gadobutrol (2.4 mmol/kg per week for 5 weeks), or saline (4.8 mL/kg per week for 5 weeks). MRI R1 mapping was performed at baseline and 1 week after the final injection to determine R1 and ΔR1. Postmortem brains from the same rats were analyzed with LA-ICP-MS elemental mapping to determine regional gadolinium concentrations. Student t tests were performed to compare results between GBCA and saline groups. Results Rats that were administered gadobenate showed gadolinium-related MRI ΔR1 in 39.5% of brain volume (ΔR1 = 0.087 second-1 ± 0.051); gadopentetate, 20.6% (ΔR1 = 0.069 second-1 ± 0.018); gadodiamide, 5.4% (ΔR1 = 0.055 second-1 ± 0.019); and gadobutrol, 2.2% (ΔR1 = 0.052 second-1 ± 0.041). Agent-specific gadolinium-related ΔR1 was detected in multiple forebrain regions (neocortex, hippocampus, dentate gyrus, thalamus, and caudate-putamen) in rats treated with gadobenate or gadopentetate, whereas rats treated with gadodiamide showed gadolinium-related ΔR1 in caudate-putamen. By contrast, LA-ICP-MS elemental mapping showed a similar regional distribution pattern of heterogeneous retained gadolinium in the forebrain of rats treated with gadobenate, gadopentetate, or gadodiamide, with the average gadolinium concentration of 0.45 μg · g-1 ± 0.07, 0.50 μg · g-1 ± 0.10, and 0.60 μg · g-1 ± 0.11, respectively. Low levels (0.01 μg · g-1 ± 0.00) of retained gadolinium were detected in the forebrain of gadobutrol-treated rats. Conclusion Differences in in vivo MRI longitudinal relaxation rate versus ex vivo elemental mass spectrometry measures of retained gadolinium in rat forebrains suggest that some forms of retained gadolinium may escape detection with MRI. © RSNA, 2022 Online supplemental material is available for this article.
Collapse
Affiliation(s)
| | | | - Nicola Lupoli
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Erich S. Franz
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Xiuping Liu
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Juliet A. Moncaster
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Katharine J. Babcock
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Hernán Jara
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Yorghos Tripodis
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Ali Guermazi
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Jorge A. Soto
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Stephan W. Anderson
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| | - Lee E. Goldstein
- From the Departments of Radiology (N.H., O.M., N.L., X.L., J.A.M.,
H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (L.E.G.), Pathology &
Laboratory Medicine (L.E.G.), Anatomy & Neurobiology (K.J.B.), and
Biostatistics (Y.T.), Boston University School of Medicine, 670 Albany St, 4th
Floor, Boston, MA 02118; Boston University Alzheimer’s Disease Research
Center (N.H., O.M., J.A.M., L.E.G.), Boston, Mass; and Center for Biometallomics
(O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., S.W.A., L.E.G.),
and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston,
Mass
| |
Collapse
|
4
|
Anderhalten L, Silva RV, Morr A, Wang S, Smorodchenko A, Saatz J, Traub H, Mueller S, Boehm-Sturm P, Rodriguez-Sillke Y, Kunkel D, Hahndorf J, Paul F, Taupitz M, Sack I, Infante-Duarte C. Different Impact of Gadopentetate and Gadobutrol on Inflammation-Promoted Retention and Toxicity of Gadolinium Within the Mouse Brain. Invest Radiol 2022; 57:677-688. [PMID: 35467573 PMCID: PMC9444290 DOI: 10.1097/rli.0000000000000884] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Accepted: 03/16/2022] [Indexed: 11/25/2022]
Abstract
OBJECTIVES Using a murine model of multiple sclerosis, we previously showed that repeated administration of gadopentetate dimeglumine led to retention of gadolinium (Gd) within cerebellar structures and that this process was enhanced with inflammation. This study aimed to compare the kinetics and retention profiles of Gd in inflamed and healthy brains after application of the macrocyclic Gd-based contrast agent (GBCA) gadobutrol or the linear GBCA gadopentetate. Moreover, potential Gd-induced neurotoxicity was investigated in living hippocampal slices ex vivo. MATERIALS AND METHODS Mice at peak of experimental autoimmune encephalomyelitis (EAE; n = 29) and healthy control mice (HC; n = 24) were exposed to a cumulative dose of 20 mmol/kg bodyweight of either gadopentetate dimeglumine or gadobutrol (8 injections of 2.5 mmol/kg over 10 days). Magnetic resonance imaging (7 T) was performed at baseline as well as at day 1, 10, and 40 post final injection (pfi) of GBCAs. Mice were sacrificed after magnetic resonance imaging and brain and blood Gd content was assessed by laser ablation-inductively coupled plasma (ICP)-mass spectrometry (MS) and ICP-MS, respectively. In addition, using chronic organotypic hippocampal slice cultures, Gd-induced neurotoxicity was addressed in living brain tissue ex vivo, both under control or inflammatory (tumor necrosis factor α [TNF-α] at 50 ng/μL) conditions. RESULTS Neuroinflammation promoted a significant decrease in T1 relaxation times after multiple injections of both GBCAs as shown by quantitative T1 mapping of EAE brains compared with HC. This corresponded to higher Gd retention within the EAE brains at 1, 10, and 40 days pfi as determined by laser ablation-ICP-MS. In inflamed cerebellum, in particular in the deep cerebellar nuclei (CN), elevated Gd retention was observed until day 40 after last gadopentetate application (CN: EAE vs HC, 55.06 ± 0.16 μM vs 30.44 ± 4.43 μM). In contrast, gadobutrol application led to a rather diffuse Gd content in the inflamed brains, which strongly diminished until day 40 (CN: EAE vs HC, 0.38 ± 0.08 μM vs 0.17 ± 0.03 μM). The analysis of cytotoxic effects of both GBCAs using living brain tissue revealed an elevated cell death rate after incubation with gadopentetate but not gadobutrol at 50 mM. The cytotoxic effect due to gadopentetate increased in the presence of the inflammatory mediator TNF-α (with vs without TNF-α, 3.15% ± 1.18% vs 2.17% ± 1.14%; P = 0.0345). CONCLUSIONS In the EAE model, neuroinflammation promoted increased Gd retention in the brain for both GBCAs. Whereas in the inflamed brains, efficient clearance of macrocyclic gadobutrol during the investigated time period was observed, the Gd retention after application of linear gadopentetate persisted over the entire observational period. Gadopentetate but not gadubutrol appeared to be neurotoxic in an ex vivo paradigm of neuronal inflammation.
Collapse
Affiliation(s)
- Lina Anderhalten
- From the Experimental and Clinical Research Center (ECRC), A Cooperation Between the Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin
| | - Rafaela V. Silva
- From the Experimental and Clinical Research Center (ECRC), A Cooperation Between the Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin
- Einstein Center for Neurosciences
| | - Anna Morr
- Department of Radiology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Berlin
| | - Shuangqing Wang
- From the Experimental and Clinical Research Center (ECRC), A Cooperation Between the Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin
| | - Alina Smorodchenko
- Institute for Translational Medicine and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg
| | - Jessica Saatz
- Bundesanstalt für Materialforschung und -prüfung, Berlin
| | - Heike Traub
- Bundesanstalt für Materialforschung und -prüfung, Berlin
| | - Susanne Mueller
- Department of Experimental Neurology and Center for Stroke Research
- NeuroCure Cluster of Excellence and Charité Core Facility 7T Experimental MRIs, Charité–Universitätsmedizin Berlin, Berlin
| | - Philipp Boehm-Sturm
- Department of Experimental Neurology and Center for Stroke Research
- NeuroCure Cluster of Excellence and Charité Core Facility 7T Experimental MRIs, Charité–Universitätsmedizin Berlin, Berlin
| | - Yasmina Rodriguez-Sillke
- Berlin Institute of Health at Charité–Universitätsmedizin Berlin, Flow & Mass Cytometry Core Facility, Berlin, Germany
| | - Désirée Kunkel
- Berlin Institute of Health at Charité–Universitätsmedizin Berlin, Flow & Mass Cytometry Core Facility, Berlin, Germany
| | - Julia Hahndorf
- Department of Radiology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Berlin
| | - Friedemann Paul
- From the Experimental and Clinical Research Center (ECRC), A Cooperation Between the Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin
| | - Matthias Taupitz
- Department of Radiology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Berlin
| | - Ingolf Sack
- Department of Radiology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Berlin
| | - Carmen Infante-Duarte
- From the Experimental and Clinical Research Center (ECRC), A Cooperation Between the Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin
| |
Collapse
|
5
|
Zhang RR, Choi C, Brunnquell CL, Hernandez R, Pinchuk AN, Grudzinski JG, Clark PA, McMillan AB, Audhya A, Jeffrey J, Kuo JS, Weichert JP. Next-Generation Cancer Magnetic Resonance Imaging With Tumor-Targeted Alkylphosphocholine Metal Analogs. Invest Radiol 2022; 57:655-663. [PMID: 36069439 PMCID: PMC9469686 DOI: 10.1097/rli.0000000000000893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES In an effort to exploit the elevated need for phospholipids displayed by cancer cells relative to normal cells, we have developed tumor-targeted alkylphosphocholines (APCs) as broad-spectrum cancer imaging and therapy agents. Radioactive APC analogs have exhibited selective uptake and prolonged tumor retention in over 50 cancer types in preclinical models, as well as over 15 cancer types in over a dozen clinical trials. To push the structural limits of this platform, we recently added a chelating moiety capable of binding gadolinium and many other metals for cancer-targeted magnetic resonance imaging (MRI), positron emission tomography imaging, and targeted radionuclide therapy. The aim of this work was to synthesize, characterize, and validate the tumor selectivity of a new broad-spectrum, tumor-targeted, macrocyclic MRI chelate, Gd-NM600, in xenograft and orthotopic tumor models. A secondary aim was to identify and track the in vivo chemical speciation and spatial localization of this new chelate Gd-NM600 in order to assess its Gd deposition properties. MATERIALS AND METHODS T1 relaxivities of Gd-NM600 were characterized in water and plasma at 1.5 T and 3.0 T. Tumor uptake and subcellular localization studies were performed using transmission electron microscopy. We imaged 8 different preclinical models of human cancer over time and compared the T1-weighted imaging results to that of a commercial macrocyclic Gd chelate, Gd-DOTA. Finally, matrix-assisted laser desorption and ionization-mass spectrometry imaging was used to characterize and map the tissue distribution of the chemical species of Gd-NM600. RESULTS Gd-NM600 exhibits high T1 relaxivity (approximately 16.4 s-1/mM at 1.5 T), excellent tumor uptake (3.95 %ID/g at 48 hours), prolonged tumor retention (7 days), and MRI conspicuity. Moreover, minimal tumor uptake saturability of Gd-NM600 was observed. Broad-spectrum tumor-specific uptake was demonstrated in 8 different human cancer models. Cancer cell uptake of Gd-NM600 via endosomal internalization and processing was revealed with transmission electron microscopy. Importantly, tissue mass spectrometry imaging successfully interrogated the spatial localization and chemical speciation of Gd compounds and also identified breakdown products of Gd species. CONCLUSIONS We have introduced a new macrocyclic cancer-targeted Gd chelate that achieves broad-spectrum tumor uptake and prolonged retention. Furthermore, we have demonstrated in vivo stability of Gd-NM600 by ultrahigh resolution MS tissue imaging. A tumor-targeted contrast agent coupled with the enhanced imaging resolution of MRI relative to positron emission tomography may transform oncologic imaging.
Collapse
Affiliation(s)
- Ray R Zhang
- Department of Radiology, University of Wisconsin School of
Medicine and Public Health, Madison, WI
- Department of Neurological Surgery, University of Wisconsin
School of Medicine and Public Health, Madison, WI
| | - Cynthia Choi
- Department of Pharmaceutical Sciences, University of
Wisconsin School of Medicine and Public Health, Madison, WI
| | - Christina L Brunnquell
- Department of Medical Physics, University of Wisconsin
School of Medicine and Public Health, Madison, WI
- University of Washington, Dell Medical School, University
of Texas at Austin, Austin, TX
| | - Reinier Hernandez
- Department of Radiology, University of Wisconsin School of
Medicine and Public Health, Madison, WI
- Department of Medical Physics, University of Wisconsin
School of Medicine and Public Health, Madison, WI
| | - Anatoly N Pinchuk
- Department of Radiology, University of Wisconsin School of
Medicine and Public Health, Madison, WI
| | - Joseph G. Grudzinski
- Department of Radiology, University of Wisconsin School of
Medicine and Public Health, Madison, WI
| | - Paul A Clark
- Department of Neurological Surgery, University of Wisconsin
School of Medicine and Public Health, Madison, WI
| | - Alan B McMillan
- Department of Radiology, University of Wisconsin School of
Medicine and Public Health, Madison, WI
| | - Anjon Audhya
- Carbone Cancer Center, University of Wisconsin School of
Medicine and Public Health, Madison, WI
| | - Justin Jeffrey
- Carbone Cancer Center, University of Wisconsin School of
Medicine and Public Health, Madison, WI
| | - John S Kuo
- Department of Neurological Surgery, University of Wisconsin
School of Medicine and Public Health, Madison, WI
- Carbone Cancer Center, University of Wisconsin School of
Medicine and Public Health, Madison, WI
- Department of Neurosurgery, Dell Medical School, University
of Texas at Austin, Austin, TX
| | - Jamey P Weichert
- Department of Radiology, University of Wisconsin School of
Medicine and Public Health, Madison, WI
- Carbone Cancer Center, University of Wisconsin School of
Medicine and Public Health, Madison, WI
| |
Collapse
|
6
|
Li H, Zhang X, Shao F, Chen J, Li L, Hong R. Continuous preparation of a nontoxic magnetic fluid as a dual-mode contrast agent for MRI. BIOMATERIALS ADVANCES 2022; 139:213004. [PMID: 35882151 DOI: 10.1016/j.bioadv.2022.213004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/26/2022] [Revised: 05/30/2022] [Accepted: 06/22/2022] [Indexed: 06/15/2023]
Abstract
Ultrasmall nanoparticle contrast agents provide dual-mode MRI. However, the application of ultrasmall nanoparticle contrast agents is limited by low manufacturing outputs and cumbersome preparation processes. Herein, we report a novel continuous-flow coprecipitation method for the preparation of the Fe3O4 nanoparticles magnetic fluid (CFCPFe) coated with ultrasmall cysteine-terminated polymethacrylic acid (Cys-PMAA). The preparation process is more coherent, simpler, and less expensive. Compared with magnetic fluids prepared by the conventional method (Cys-PMAA@Fe3O4), CFCPFe has smaller particle sizes (3.27 ± 0.93 nm). Moreover, CFCPFe demonstrates excellent stability for >180 days with different pH values (pH = 2-12) and salt concentrations (up to 2 mol/L). In addition, HEK293T cytotoxicity tests, hemolysis tests, and H&E tissue sections show excellent in vitro and in vivo biocompatibility. In vitro magnetic resonance imaging (MRI) at 1.5 T shows that the r2 value (50.51 mM-1·s-1) of CFCPFe is slightly lower than that of Combidex (r2 = 65 mM-1·s-1) and that the r1 value (9.54 mM-1·s-1) is 2.7 times higher than that of Gd-DTPA (r1 = 3.5 mM-1·s-1). Finally, in vivo imaging shows that CFCPFe reaches the tumor region of the mouse liver cancer model, and a small tumor can be observed in dual-mode imaging. This work offers an effective method for the preparation of a low-cost, stable, and biocompatible ultrasmall contrast agent exhibiting a strong magnetic-imaging effect for dual-mode imaging.
Collapse
Affiliation(s)
- Hongcai Li
- College of Chemical Engineering, Fuzhou University, Fuzhou, Fujian 350108, China
| | - Xing Zhang
- College of Chemical Engineering, Fuzhou University, Fuzhou, Fujian 350108, China
| | - Fei Shao
- Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, China
| | - Jian Chen
- College of Electrical Engineering and Automation, Fuzhou University, Fuzhou, Fujian 350108, China
| | - Linfu Li
- College of Pharmacy, Gannan Medical University, Ganzhou, Jiangxi 341000, China..
| | - Ruoyu Hong
- College of Chemical Engineering, Fuzhou University, Fuzhou, Fujian 350108, China..
| |
Collapse
|
7
|
Funke SKI, Factor C, Rasschaert M, Lezius L, Sperling M, Karst U, Robert P. Long-term Gadolinium Retention in the Healthy Rat Brain: Comparison between Gadopiclenol, Gadobutrol, and Gadodiamide. Radiology 2022; 305:179-189. [PMID: 35727155 DOI: 10.1148/radiol.212600] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Background Safety concerns caused by gadolinium retention call for the development of high-relaxivity gadolinium-based contrast agents (GBCAs) allowing minimal dosing. Purpose To investigate brain gadolinium retention in healthy rats after exposure to gadopiclenol (Elucirem, Guerbet; macrocyclic GBCA) compared with gadobutrol (Gadovist or Gadavist, Bayer; macrocyclic GBCA) and gadodiamide (Omniscan, GE Healthcare; linear GBCA) over 1 year. Materials and Methods In this study conducted between May 2018 and April 2020, 9-week-old healthy Sprague Dawley rats received five injections of either gadopiclenol, gadobutrol, or gadodiamide (2.4 mmol of gadolinium per kilogram of body weight for each), or saline (control animals) over a period of 5 weeks. Rats were randomly assigned to different groups (six female and six male rats per group). MRI examinations were performed before euthanasia at 1, 3, 5, or 12 months after the last injection. Brains were sampled to determine the total gadolinium content via inductively coupled plasma mass spectrometry (ICP-MS), to characterize gadolinium species with size exclusion chromatography (SEC)-ICP-MS, and to perform elemental mapping with laser ablation (LA)-ICP-MS. Mann-Whitney tests were performed on pairwise comparisons of the same time points. Results For both macrocyclic agents, no T1 signal hyperintensities were observed in the cerebellum, and approximately 80% of gadolinium washout was found between 1 month (gadobutrol, 0.30 nmol/g; gadopiclenol, 0.37 nmol/g) and 12 months (gadobutrol, 0.062 nmol/g; gadopiclenol, 0.078 nmol/g). After 12 months, only low-molecular-weight gadolinium species were detected in the soluble fraction. Gadodiamide led to significantly higher gadolinium concentrations after 1 month in the cerebellum (gadodiamide, 2.65 nmol/g; P < .001 vs both macrocyclics) combined with only 15% washout after 12 months (gadodiamide, 2.25 nmol/g) and with gadolinium detected bound to macromolecules. Elemental bioimaging enabled visualization of gadolinium deposition patterns colocalized with iron. Conclusion Gadopiclenol and gadobutrol demonstrated similar in vivo distribution and washout of gadolinium in the healthy rat brain, markedly differing from gadodiamide up to 12 months after the last injection. © RSNA, 2022 Online supplemental material is available for this article.
Collapse
Affiliation(s)
- Sabrina K I Funke
- From the Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (S.K.I.F., L.L., M.S., U.K.); and Department of Research and Innovation, Guerbet Group, BP57400, Roissy 95943, France (C.F., M.R., P.R.)
| | - Cécile Factor
- From the Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (S.K.I.F., L.L., M.S., U.K.); and Department of Research and Innovation, Guerbet Group, BP57400, Roissy 95943, France (C.F., M.R., P.R.)
| | - Marlène Rasschaert
- From the Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (S.K.I.F., L.L., M.S., U.K.); and Department of Research and Innovation, Guerbet Group, BP57400, Roissy 95943, France (C.F., M.R., P.R.)
| | - Lena Lezius
- From the Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (S.K.I.F., L.L., M.S., U.K.); and Department of Research and Innovation, Guerbet Group, BP57400, Roissy 95943, France (C.F., M.R., P.R.)
| | - Michael Sperling
- From the Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (S.K.I.F., L.L., M.S., U.K.); and Department of Research and Innovation, Guerbet Group, BP57400, Roissy 95943, France (C.F., M.R., P.R.)
| | - Uwe Karst
- From the Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (S.K.I.F., L.L., M.S., U.K.); and Department of Research and Innovation, Guerbet Group, BP57400, Roissy 95943, France (C.F., M.R., P.R.)
| | - Philippe Robert
- From the Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany (S.K.I.F., L.L., M.S., U.K.); and Department of Research and Innovation, Guerbet Group, BP57400, Roissy 95943, France (C.F., M.R., P.R.)
| |
Collapse
|
8
|
Fingerhut S, Buchholz R, Bücker P, Clasen W, Sperling M, Müller KM, Rehkämper J, Radbruch A, Richter H, Jeibmann A, Karst U. Gadolinium retention in the tunica media of arterial walls - a complementary study using elemental bioimaging and immunogold staining. Metallomics 2022; 14:6575571. [PMID: 35482657 DOI: 10.1093/mtomcs/mfac029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Accepted: 04/08/2022] [Indexed: 11/14/2022]
Abstract
Gadolinium (Gd) deposition has been found in both animal and human tissues after serial injections of gadolinium-based contrast agents (GBCAs). Without the knowledge of which tissues are most affected, it is difficult to determine whether Gd accumulation could lead to any pathological changes. The current study aims at investigating histological sections of three patients who were exposed to GBCAs during their lifetime, and identify areas of Gd accumulation. Tissue sections of three autopsy cases were investigated by laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) to assess the distribution of Gd, and the deposition within tissue sections was quantified. Additional application of laser ablation-inductively coupled plasma-optical emission spectroscopy (LA-ICP-OES) enabled a sensitive detection of calcium (Ca) in the vessel walls, which is usually impeded in LA-ICP-MS due to the isobaric interference with argon. Complementary LA-ICP-MS and LA-ICP-OES analysis revealed that Gd was co-localized with zinc and calcium, in the area where smooth muscle actin was present. Notably, high levels of Gd were found in the tunica media of arterial walls, which requires further research into potential Gd-related toxicity in this specific location.
Collapse
Affiliation(s)
- Stefanie Fingerhut
- Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstraße 28/30, 48149 Münster, Germany
| | - Rebecca Buchholz
- Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstraße 28/30, 48149 Münster, Germany
| | - Patrick Bücker
- Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstraße 28/30, 48149 Münster, Germany
| | - Wolfgang Clasen
- Clinic for Internal Medicine, Herz-Jesu-Krankenhaus Hiltrup GmbH, Westfalenstraße 109, 48165 Münster-Hiltrup, Germany
| | - Michael Sperling
- Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstraße 28/30, 48149 Münster, Germany
| | - Klaus-Michael Müller
- Gerhard-Domagk-Institute for Pathology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany
| | - Jan Rehkämper
- Gerhard-Domagk-Institute for Pathology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.,Department of Pathology, University Hospital Köln, Kerpener Straße 62, 50937 Köln, Germany
| | - Alexander Radbruch
- Clinic for Neuroradiology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.,Clinical Neuroimaging, German Center for Neurodegenerative Diseases, Venusberg Campus 1, 53127 Bonn, Germany
| | - Henning Richter
- Clinical Neuroimaging, German Center for Neurodegenerative Diseases, Venusberg Campus 1, 53127 Bonn, Germany.,Diagnostic Imaging Research Unit (DIRU), Clinic for Diagnostic Imaging, Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 258c, 8057 Zurich, Switzerland
| | - Astrid Jeibmann
- Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149 Münster Germany
| | - Uwe Karst
- Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstraße 28/30, 48149 Münster, Germany
| |
Collapse
|
9
|
Bücker P, Funke SKI, Factor C, Rasschaert M, Robert P, Sperling M, Karst U. Combined speciation analysis and elemental bioimaging provides new insight into gadolinium retention in kidney. Metallomics 2022; 14:6527577. [PMID: 35150284 DOI: 10.1093/mtomcs/mfac004] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Accepted: 01/31/2022] [Indexed: 11/14/2022]
Abstract
This study uses a leaching approach in combination with elemental bioimaging and speciation analysis to obtain insight into the gadolinium species present in the kidney of rats that were treated with either a linear or a macrocyclic gadolinium-based contrast agent. Fresh frozen thin sections of the harvested kidneys were immersed halfway into water to wash out hydrophilic species and subsequently analyzed by laser ablation-inductively coupled plasma-mass spectrometry. The water-extracted gadolinium species were analyzed by means of hydrophilic interaction liquid chromatography-inductively coupled plasma-mass spectrometry. Information on the water-soluble species could not only be obtained from the full kidney, but also be traced back to its localization in the tissue. On longitudinal kidney sections treated with gadobutrol, it was found that water-insoluble, permanent Gd depositions were mainly located in the renal cortex, while water-soluble species were found in the medulla, which contains the intact contrast agent up to one year after injection. Moreover, kidney samples from gadodiamide-treated rats showed more water-insoluble Gd deposition in both cortex and medulla, while the concentration of intact contrast agent in the water-soluble fraction was below the limit of detection after twelve months. In conclusion, this rapid approach allowed the spatially resolved differentiation between water-soluble and insoluble gadolinium deposition and is therefore capable of generating new insight into the retention and transportation behavior of gadolinium.
Collapse
Affiliation(s)
- Patrick Bücker
- Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstrasse 28/30, Münster 48149, Germany
| | - Sabrina K I Funke
- Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstrasse 28/30, Münster 48149, Germany
| | - Cécile Factor
- Department of Research and Innovation, Guerbet, Roissy CDG, France
| | | | - Philippe Robert
- Department of Research and Innovation, Guerbet, Roissy CDG, France
| | - Michael Sperling
- Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstrasse 28/30, Münster 48149, Germany
| | - Uwe Karst
- Institute of Inorganic and Analytical Chemistry, University of Münster, Corrensstrasse 28/30, Münster 48149, Germany
| |
Collapse
|
10
|
Davies J, Siebenhandl-Wolff P, Tranquart F, Jones P, Evans P. Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration. Arch Toxicol 2022; 96:403-429. [PMID: 34997254 PMCID: PMC8837552 DOI: 10.1007/s00204-021-03189-8] [Citation(s) in RCA: 27] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Accepted: 11/02/2021] [Indexed: 12/12/2022]
Abstract
Gadolinium-based contrast agents (GBCAs) have transformed magnetic resonance imaging (MRI) by facilitating the use of contrast-enhanced MRI to allow vital clinical diagnosis in a plethora of disease that would otherwise remain undetected. Although over 500 million doses have been administered worldwide, scientific research has documented the retention of gadolinium in tissues, long after exposure, and the discovery of a GBCA-associated disease termed nephrogenic systemic fibrosis, found in patients with impaired renal function. An understanding of the pharmacokinetics in humans and animals alike are pivotal to the understanding of the distribution and excretion of gadolinium and GBCAs, and ultimately their potential retention. This has been well studied in humans and more so in animals, and recently there has been a particular focus on potential toxicities associated with multiple GBCA administration. The purpose of this review is to highlight what is currently known in the literature regarding the pharmacokinetics of gadolinium in humans and animals, and any toxicity associated with GBCA use.
Collapse
Affiliation(s)
- Julie Davies
- GE Healthcare, Pollards Wood, Nightingales Lane, Chalfont St. Giles, UK.
| | | | | | - Paul Jones
- GE Healthcare, Pollards Wood, Nightingales Lane, Chalfont St. Giles, UK
| | - Paul Evans
- GE Healthcare, Pollards Wood, Nightingales Lane, Chalfont St. Giles, UK
| |
Collapse
|
11
|
Laser Ablation ICP-MS Analysis of Chemically Different Regions of Rat Prostate Gland with Implanted Cancer Cells. APPLIED SCIENCES-BASEL 2022. [DOI: 10.3390/app12031474] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The comparison of tissues analyzed by LA-ICP-MS is challenging in many aspects, both medical and mathematical. The concept of distinguishing regions of interest (ROIs) was proposed in the literature, allowing for data reduction and targeted comparative analysis. ROIs can be drawn before any analysis, by indicating the anatomical parts of tissue, or after the first step of analysis, by using elemental distribution maps and characteristic regions of enrichment in selected elements. A simple method for identifying different regions, without the manual extraction of image fragments, is highly needed in biological experiments, where large groups of individuals (with samples taken from each of them) is very common. In the present study, two ROIs were distinguished: (1) tissue-rich in fat (and tissue-poor in water); and (2) tissue-rich in water (and tissue-poor in fat). ROIs were extracted mathematically, using an algorithm based on the relationship between 13C and 23Na signal intensities. A cut-off point was indicated in the point of the simultaneous decrease in 13C and increase in 23Na signal intensity. Separate analyses of chemically different ROIs allow for targeted comparison, which is a great advantage of laser ablation over liquid introductions to ICP-MS. In the present experiment, tissues were provided from animals with implanted prostate cancer cells as well as supplemented with mineral compounds particularly important both for prostate gland functions (Zn and Se) and neoplastic processes (Ca, Fe, and Cu). One of the goals was to try to determine whether dietary supplementation qualitatively and quantitatively affects the mineral composition of the prostate gland.
Collapse
|
12
|
Chung JG, Holtkamp H, Nieuwoudt M, Matthews H, Aguergaray C, Morrow S, Caughey M, Poppito N, Jarrett P. The combination of Raman Spectroscopy and Mass Spectrometry to investigate cutaneous metallosis. Br J Dermatol 2021; 187:447-448. [PMID: 34811723 DOI: 10.1111/bjd.20902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 11/09/2021] [Accepted: 11/17/2021] [Indexed: 11/28/2022]
Abstract
Skin is uniquely accessible to investigation by modern scientific methods. Raman spectroscopy is a non-invasive technology for in-vivo analysis of molecular composition. Furthermore, a skin biopsy examined with Laser ablation - Inductively Coupled Plasma - Mass Spectrometry (LA-ICP-MS) provides high resolution multi-element mapping with high sensitivity and precision for exogenous metals in biological tissue which have no intrinsic abundance. This technique has been successfully applied to identify a variety of metals including gadolinium in cerebral vessel walls after contrast studies (1) . These two techniques were used to investigate metallosis from a shoulder joint replacement.
Collapse
Affiliation(s)
- J G Chung
- Department of Dermatology, Middlemore Hospital, Auckland, New Zealand
| | - H Holtkamp
- The Photon Factory, The University of Auckland, Auckland, New Zealand.,School of Chemical Sciences, The University of Auckland, Auckland, New Zealand.,The Dodd-Walls Centre for Photonic and Quantum Technologies, The University of Otago, Dunedin, New Zealand
| | - M Nieuwoudt
- The Photon Factory, The University of Auckland, Auckland, New Zealand.,School of Chemical Sciences, The University of Auckland, Auckland, New Zealand.,The Dodd-Walls Centre for Photonic and Quantum Technologies, The University of Otago, Dunedin, New Zealand.,The MacDiarmid Institute for Advanced Materials and Nanotechnology, Victoria University, New Zealand
| | - H Matthews
- The Photon Factory, The University of Auckland, Auckland, New Zealand.,School of Chemical Sciences, The University of Auckland, Auckland, New Zealand
| | - C Aguergaray
- The Photon Factory, The University of Auckland, Auckland, New Zealand.,The Dodd-Walls Centre for Photonic and Quantum Technologies, The University of Otago, Dunedin, New Zealand.,Department of Physics, The University of Auckland, Auckland, New Zealand
| | - S Morrow
- School of Chemical Sciences, The University of Auckland, Auckland, New Zealand
| | - M Caughey
- 92 Mountain Rd, Epsom, Auckland, New Zealand
| | - N Poppito
- Department of Histopathology, Middlemore Hospital, Auckland, New Zealand
| | - P Jarrett
- Department of Dermatology, Middlemore Hospital, Auckland, New Zealand.,The Department of Medicine, The University of Auckland, Auckland, New Zealand
| |
Collapse
|
13
|
Michali-Stolarska M, Tukiendorf A, Zacharzewska-Gondek A, Jacków-Nowicka J, Chrzanowska J, Trybek G, Bladowska J. MRI Protocol for Pituitary Assessment in Children with Growth or Puberty Disorders-Is Gadolinium Contrast Administration Actually Needed? J Clin Med 2021; 10:jcm10194598. [PMID: 34640616 PMCID: PMC8509364 DOI: 10.3390/jcm10194598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 09/28/2021] [Accepted: 10/01/2021] [Indexed: 11/23/2022] Open
Abstract
The aim of this study was to assess the diagnostic value of non-contrast pituitary MRI in children with growth or puberty disorders (GPDs) and to determine the criteria indicating the necessity to perform post-contrast examination. A retrospective study included re-analysis of 567 contrast-enhanced pituitary MRIs of children treated in a tertiary reference center. Two sets of sequences were created from each MRI examination: Set 1, including common sequences without contrast administration, and Set 2, which included common pre- and post-contrast sequences (conventional MRI examination). The differences in the visibility of pituitary lesions between pairs of sets were statistically analyzed. The overall frequency of Rathke’s cleft cysts was 11.6%, ectopic posterior pituitary 3.5%, and microadenomas 0.9%. Lesions visible without contrast administration accounted for 85% of cases. Lesions not visible before and diagnosed only after contrast injection accounted for only 0.18% of all patients. Statistical analysis showed the advantage of the antero-posterior (AP) pituitary dimension over the other criteria in determining the appropriateness of using contrast in pituitary MRIs. The AP dimension was the most significant factor in logistic regression analysis: OR = 2.23, 95% CI, 1.35–3.71, p-value = 0.002, and in ROC analysis: AUC: 72.9% with a cut-off value of 7.5 mm, with sensitivity/specificity rates of 69.2%/73.5%. In most cases, the use of gadolinium-based contrast agent (GBCA) in pituitary MRI in children with GPD is unnecessary. The advantages of GBCA omission include shortening the time of MRI examination and of general anesthesia; saving time for other examinations, thus increasing the availability of MRI for waiting children; and acceleration in their further clinical management.
Collapse
Affiliation(s)
- Marta Michali-Stolarska
- Department of General and Interventional Radiology and Neuroradiology, Wroclaw Medical University, 50-367 Wroclaw, Poland; (M.M.-S.); (J.J.-N.); (J.B.)
| | - Andrzej Tukiendorf
- Department of Public Health, Wroclaw Medical University, 50-367 Wroclaw, Poland;
| | - Anna Zacharzewska-Gondek
- Department of General and Interventional Radiology and Neuroradiology, Wroclaw Medical University, 50-367 Wroclaw, Poland; (M.M.-S.); (J.J.-N.); (J.B.)
- Correspondence: ; Tel.: +48-(71)-733-1668; Fax: +48-(71)-734-1669
| | - Jagoda Jacków-Nowicka
- Department of General and Interventional Radiology and Neuroradiology, Wroclaw Medical University, 50-367 Wroclaw, Poland; (M.M.-S.); (J.J.-N.); (J.B.)
| | - Joanna Chrzanowska
- Department of Developmental Endocrinology and Diabetology, Wroclaw Medical University, 50-367 Wroclaw, Poland;
| | - Grzegorz Trybek
- Department of Oral Surgery, Pomeranian Medical University in Szczecin, 70-204 Szczecin, Poland;
| | - Joanna Bladowska
- Department of General and Interventional Radiology and Neuroradiology, Wroclaw Medical University, 50-367 Wroclaw, Poland; (M.M.-S.); (J.J.-N.); (J.B.)
| |
Collapse
|
14
|
MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis. Magn Reson Imaging Clin N Am 2021; 28:497-507. [PMID: 33040991 DOI: 10.1016/j.mric.2020.06.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Gadolinium (Gd)-based contrast agents (GBCAs) have revolutionized of MR imaging, enabling physicians to obtain life-saving medical information that often cannot be obtained with unenhanced MR imaging or other imaging modalities. Since regulatory approval in 1988, more than 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile. Recent evidence has demonstrated, however, that a small fraction of Gd is retained in human tissues. No direct correlation between Gd retention and clinical effects has been confirmed; however, a subset of patients have attributed various symptoms to GBCA exposure. This review details current knowledge regarding GBCA safety.
Collapse
|
15
|
Davies J, Marino M, Smith APL, Crowder JM, Larsen M, Lowery L, Castle J, Hibberd MG, Evans PM. Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure. Sci Rep 2021; 11:13950. [PMID: 34230532 PMCID: PMC8260729 DOI: 10.1038/s41598-021-93147-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 06/21/2021] [Indexed: 01/20/2023] Open
Abstract
Gadolinium based contrast agents (GBCA) are used to image patients using magnetic resonance (MR) imaging. In recent years, there has been controversy around gadolinium retention after GBCA administration. We sought to evaluate the potential toxicity of gadolinium in the rat brain up to 1-year after repeated gadodiamide dosing and tissue retention kinetics after a single administration. Histopathological and ultrastructural transmission electron microscopy (TEM) analysis revealed no findings in rats administered a cumulative dose of 12 mmol/kg. TEM-energy dispersive X-ray spectroscopy (TEM-EDS) localization of gadolinium in the deep cerebellar nuclei showed ~ 100 nm electron-dense foci in the basal lamina of the vasculature. Laser ablation-ICP-MS (LA-ICP-MS) showed diffuse gadolinium throughout the brain but concentrated in perivascular foci of the DCN and globus pallidus with no observable tissue injury or ultrastructural changes. A single dose of gadodiamide (0.6 mmol/kg) resulted in rapid cerebrospinal fluid (CSF) and blood clearance. Twenty-weeks post administration gadolinium concentrations in brain regions was reduced by 16-72-fold and in the kidney (210-fold), testes (194-fold) skin (44-fold), liver (42-fold), femur (6-fold) and lung (64-fold). Our findings suggest that gadolinium does not lead to histopathological or ultrastructural changes in the brain and demonstrate in detail the kinetics of a human equivalent dose over time in a pre-clinical model.
Collapse
Affiliation(s)
- Julie Davies
- GE Healthcare, Pollards Wood, Nightingales lane, Chalfont St. Giles, UK.
| | - Michael Marino
- GE Global Research Centre, 1 Research Circle, Niskayuna, NY, USA
| | - Adrian P L Smith
- GE Healthcare, Pollards Wood, Nightingales lane, Chalfont St. Giles, UK
| | - Janell M Crowder
- GE Global Research Centre, 1 Research Circle, Niskayuna, NY, USA
| | - Michael Larsen
- GE Global Research Centre, 1 Research Circle, Niskayuna, NY, USA
| | - Lisa Lowery
- GE Global Research Centre, 1 Research Circle, Niskayuna, NY, USA
| | - Jason Castle
- GE Global Research Centre, 1 Research Circle, Niskayuna, NY, USA
| | | | - Paul M Evans
- GE Healthcare, Pollards Wood, Nightingales lane, Chalfont St. Giles, UK
| |
Collapse
|
16
|
Hausmann D, Perignon V, Grabherr R, Weiland E, Nickel MD, Murer M, Bosshard L, Prummer M, Kubik-Huch RA. Can Dynamic Contrast-enhanced MRI Contribute to Improved Assessment of Rectosigmoid Involvement in Deep Infiltrating Endometriosis? In Vivo 2021; 35:2217-2226. [PMID: 34182500 DOI: 10.21873/invivo.12494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 05/05/2021] [Accepted: 05/06/2021] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM To determine whether a prototypical compressed-sensing volume-interpolated breath-hold (csVIBE) provides diagnostic value in detecting rectosigmoid infiltration in deep infiltrating endometriosis (DIE). PATIENTS AND METHODS csVIBE was employed in 151 women undergoing pelvic magnetic resonance imaging, of whom 43 had undergone surgery for suspected endometriosis. The accuracy of T2-weighted BLADE and BLADE/csVIBE, additional diagnostic value of csVIBE, and diagnostic confidence were rated by two readers. Additionally, the presence of the "mushroom cap sign" was assessed on BLADE and csVIBE. RESULTS The diagnostic accuracy, sensitivity, and specificity of BLADE and BLADE/csVIBE were not significantly different between Readers A and B. For both readers, the confidence in the diagnosis increased with csVIBE, but this increase in the odds ratio was not significant for both readers. Both readers preferred csVIBE over BLADE with regard to detection of the "mushroom cap sign." CONCLUSION csVIBE may provide a diagnostic benefit for surgical strategy selection through better delineation of the "mushroom cap sign."
Collapse
Affiliation(s)
- Daniel Hausmann
- Department of Radiology, Kantonsspital Baden, Baden, Switzerland; .,Department of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | | | - Regula Grabherr
- Department of Gynecology, Kantonsspital Baden, Baden, Switzerland
| | - Elisabeth Weiland
- MR Applications Predevelopment, Siemens Healthcare GmbH, Erlangen, Germany
| | | | - Maurus Murer
- Department of Pathology, Kantonsspital Baden, Baden, Switzerland
| | - Lars Bosshard
- Nexus Personalized Health Technologies, ETH Zurich, and Swiss Institute for Bioinformatics (SIB), Zurich, Switzerland
| | - Michael Prummer
- Nexus Personalized Health Technologies, ETH Zurich, and Swiss Institute for Bioinformatics (SIB), Zurich, Switzerland
| | | |
Collapse
|
17
|
DeLano MC, Spampinato MV, Chang EY, Barr RG, Lichtenstein RJ, Colosimo C, Vymazal J, Wen Z, Lin DDM, Kirchin MA, Pirovano G. Dose-Lowering in Contrast-Enhanced MRI of the Central Nervous System: A Retrospective, Parallel-Group Comparison Using Gadobenate Dimeglumine. J Magn Reson Imaging 2021; 54:1660-1675. [PMID: 34018290 PMCID: PMC9290706 DOI: 10.1002/jmri.27731] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 05/05/2021] [Accepted: 05/07/2021] [Indexed: 11/16/2022] Open
Abstract
Background Concerns over gadolinium (Gd) retention encourage the use of lower Gd doses. However, lower Gd doses may compromise imaging performance. Higher relaxivity gadobenate may be suited to reduced dose protocols. Purpose To compare 0.05 mmol/kg and 0.1 mmol/kg gadobenate in patients undergoing enhanced MRI of the central nervous system (CNS). Study Type Retrospective, multicenter. Population Three hundred and fifty‐two patients receiving 0.05 (n = 181) or 0.1 (n = 171) mmol/kg gadobenate. Field Strength/Sequences 1.5 T and 3.0 T/precontrast and postcontrast T1‐weighted spin echo/fast spin echo (SE/FSE) and/or gradient echo/fast field echo (GRE/FFE); precontrast T2‐weighted FSE and T2‐FLAIR. Assessment Images of patients with extra‐axial lesions at 1.5 T or any CNS lesion at 3.0 T were reviewed by three blinded, independent neuroradiologists for qualitative (lesion border delineation, internal morphology visualization, contrast enhancement; scores from 1 = poor to 4 = excellent) and quantitative (lesion‐to‐brain ratio [LBR], contrast‐to‐noise ratio [CNR]; SI measurements at regions‐of‐interest on lesion and normal parenchyma) enhancement measures. Noninferiority of 0.05 mmol/kg gadobenate was determined for each qualitative endpoint if the lower limit of the 95% confidence interval (CI) for the difference in precontrast + postcontrast means was above a noninferiority margin of −0.4. Statistical Tests Student's t‐test for comparison of mean qualitative endpoint scores, Wilcoxon signed rank test for comparison of LBR and CNR values; Wilcoxon rank sum test for comparison of SI changes. Tests were significant for P < 0.05. Results The mean change from precontrast to precontrast + postcontrast was significant for all endpoints. Readers 1, 2, and 3 evaluated 304, 225, and 249 lesions for 0.05 mmol/kg gadobenate, and 382, 309, and 298 lesions for 0.1 mmol/kg gadobenate. The lower limit of the 95% CI was above −0.4 for all comparisons. Significantly, higher LBR and CNR was observed with the higher dose. Data Conclusion 0.05 mmol/kg gadobenate was noninferior to 0.1 mmol/kg gadobenate for lesion visualization. Evidence Level 2 Technical Efficacy Stage 3
Collapse
Affiliation(s)
- Mark C DeLano
- Spectrum Health System, Advanced Radiology Services PC, Division of Radiology and Biomedical Imaging, College of Human Medicine, Michigan State University, Michigan, USA
| | - Maria Vittoria Spampinato
- Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Eric Y Chang
- Radiology Service, VA San Diego Healthcare System, San Diego, California, USA
| | - Richard G Barr
- Department of Radiology, Rootstown, Northeastern Ohio Medical University, Rootstown, Ohio, USA
| | | | - Cesare Colosimo
- Institute of Radiology, Radiodiagnostica e Neuroradiologia, Fondazione Policlinico Universitario "A. Gemelli", Università Cattolica del Sacro Cuore, Rome, Italy
| | - Josef Vymazal
- Department of Radiology, Na Homolce Hospital, Prague, Czech Republic
| | - Zhibo Wen
- Department of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou, China
| | - Doris D M Lin
- Division of Neuroradiology, Russell H. Morgan Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Miles A Kirchin
- Global Medical & Regulatory Affairs, Bracco Imaging SpA, Milan, Italy
| | - Gianpaolo Pirovano
- Global Medical & Regulatory Affairs, Bracco Diagnostics Inc., Monroe, New Jersey, USA
| |
Collapse
|
18
|
Lehmann Urban D, Mohamed M, Ludolph AC, Kassubek J, Rosenbohm A. The value of qualitative muscle MRI in the diagnostic procedures of myopathies: a biopsy-controlled study in 191 patients. Ther Adv Neurol Disord 2021; 14:1756286420985256. [PMID: 33737953 PMCID: PMC7934066 DOI: 10.1177/1756286420985256] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2020] [Accepted: 12/11/2020] [Indexed: 11/17/2022] Open
Abstract
Background and aims The role of muscle magnetic resonance imaging (MRI) in the diagnostic procedures of myopathies is still controversially discussed. The current study was designed to analyze the status of qualitative muscle MRI, electromyography (EMG), and muscle biopsy in different cases of clinically suspected myopathy. Methods A total of 191 patients (male: n = 112, female: n = 79) with suspected myopathy who all received muscle MRI, EMG, and muscle biopsy for diagnostic reasons were studied, with the same location of biopsy and muscle MRI (either upper or lower extremities or paravertebral muscles). Muscle MRIs were analyzed using standard rating protocols by two different raters independently. Results Diagnostic findings according to biopsy results and genetic testing were as follow: non-inflammatory myopathy: n = 65, inflammatory myopathy (myositis): n = 51, neurogenic: n = 18, unspecific: n = 23, and normal: n = 34. The majority of patients showed myopathic changes in the EMG. Edema, atrophy, muscle fatty replacement, and contrast medium enhancement (CM uptake) in MRI were observed across all final diagnostic groups. Only 30% of patients from the myositis group (n = 15) showed CM uptake. Discussion and conclusion The study provides guidance in the definition of the impact of muscle MRI in suspected myopathy: despite being an important diagnostic tool, qualitative MRI findings could not distinguish different types of neuromuscular diagnostic groups in comparison with the gold standard histopathologic diagnosis and/or genetic testing. The results suggest that neither muscle edema nor gadolinium enhancement are able to secure a diagnosis of myositis. The current results do not support qualitative MRI as aiding in the diagnostic distinction of various myopathies. Quantitative muscle MRI is, however, useful in the diagnostic procedure of a suspected neuromuscular disease, especially with regard to assessing progression of a chronic myopathy by quantification of the degree of atrophy and fatty replacement and in exploring patterns of muscle group involvements in certain genetic myopathies.
Collapse
Affiliation(s)
| | - Mohamed Mohamed
- Department of Radiology/Neuroradiology, University and Rehabilitation Clinics Ulm, Ulm, Germany
| | | | - Jan Kassubek
- Department of Neurology, Ulm University, Ulm, Germany
| | - Angela Rosenbohm
- Department of Neurology, Ulm University, Oberer Eselsberg 45, Ulm, Germany
| |
Collapse
|
19
|
Xie J, Haeckel A, Hauptmann R, Ray IP, Limberg C, Kulak N, Hamm B, Schellenberger E. Iron(III)-tCDTA derivatives as MRI contrast agents: Increased T 1 relaxivities at higher magnetic field strength and pH sensing. Magn Reson Med 2021; 85:3370-3382. [PMID: 33538352 DOI: 10.1002/mrm.28664] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Revised: 12/09/2020] [Accepted: 12/09/2020] [Indexed: 12/13/2022]
Abstract
PURPOSE Low molecular weight iron(III) complex-based contrast agents (IBCA) including iron(III) trans-cyclohexane diamine tetraacetic acid [Fe(tCDTA)]- could serve as alternatives to gadolinium-based contrast agents in MRI. In search for IBCA with enhanced properties, we synthesized derivatives of [Fe(tCDTA)]- and compared their contrast effects. METHODS Trans-cyclohexane diamine tetraacetic acid (tCDTA) was chemically modified in 2 steps: first the monoanhydride of Trans-cyclohexane diamine tetraacetic acid was generated, and then it was coupled to amines in the second step. After purification, the chelators were analyzed by high-performance liquid chromatography, mass spectrometry, and NMR spectrometry. The chelators were complexed with iron(III), and the relaxivities of the complexes were measured at 0.94, 1.5, 3, and 7 Tesla. Kinetic stabilities of the complexes were analyzed spectrophotometrically and the redox properties by cyclic voltammetry. RESULTS Using ethylenediamine (en) and trans-1,4-diaminocyclohexane, we generated monomers and dimers of tCDTA: en-tCDTA, en-tCDTA-dimer, trans-1,4-diaminocyclohexane-tCDTA, and trans-1,4-diaminocyclohexane-tCDTA-dimer. The iron(III) complexes of these derivatives had similarly high stabilities as [Fe(tCDTA)]- . The iron(III) complexes of the trans-1,4-diaminocyclohexane derivatives had higher T1 relaxivities than [Fe(tCDTA)]- that increased with increasing magnetic field strengths and were highest at 6.8 L·mmol-1 ·s-1 per molecule for the dimer. Remarkably, the relaxivity of [Fe(en-tCDTA)]+ had a threefold increase from neutral pH toward pH6. CONCLUSION Four iron(III) complexes with similar stability in comparison to [Fe(tCDTA)]- were synthesized. The relaxivities of trans-1,4-diaminocyclohexane-tCDTA and trans-1,4-diaminocyclohexane-tCDTA-dimer complexes were in the same range as gadolinium-based contrast agents at 3 Tesla. The [Fe(en-tCDTA)]+ complex is a pH sensor at weakly acidic pH levels, which are typical for various cancer types.
Collapse
Affiliation(s)
- Jing Xie
- Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Akvile Haeckel
- Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Ralf Hauptmann
- Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | | | - Christian Limberg
- Department of Chemistry, Humboldt-Universität zu Berlin, Berlin, Germany
| | - Nora Kulak
- Institute of Chemistry, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany
| | - Bernd Hamm
- Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Eyk Schellenberger
- Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
20
|
Deng LH, Jiang H, Lu FL, Wang HW, Pu Y, Wu CQ, Tang HJ, Xu Y, Chen TW, Zhu J, Shen CY, Zhang XM. Size and PEG Length-Controlled PEGylated Monocrystalline Superparamagnetic Iron Oxide Nanocomposite for MRI Contrast Agent. Int J Nanomedicine 2021; 16:201-211. [PMID: 33447035 PMCID: PMC7802780 DOI: 10.2147/ijn.s271461] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2020] [Accepted: 11/10/2020] [Indexed: 12/19/2022] Open
Abstract
OBJECTIVE PEGylated superparamagnetic iron oxide (SPIO) is the most promising alternatives to gadolinium-based contrast agents (GBCAs) in MRI. This paper is to explore the imaging effects of PEGylated SPIO, which is influenced by particle sizes and surface polyethylene glycol (PEG) coating, using as MRI contrast agents at different magnetic field intensities. METHODS Firstly, nine PEGylated monocrystalline SPIO nanoparticles with different nanocrystal sizes and different molecular weights PEG coating were prepared, and then physical and biological properties were analyzed. Finally, MRI imaging in vivo was performed to observe the imaging performance. RESULTS Nine PEGylated monocrystalline SPIO nanoparticles have good relaxivities, serum stability, and biosecurity. At the same time, they show different imaging characteristics at different magnetic field intensities. Eight-nanometer SPIO@PEG5k is an effective T 2 contrast agent at 3.0 T (r 2/r 1 = 14.0), is an ideal T 1-T 2 dual-mode contrast agent at 1.5 T (r 2/r 1 = 6.52), and is also an effective T 1 contrast agent at 0.5 T (r 2/r 1 = 2.49), while 4-nm SPIO@PEG5k is a T 1-T 2 dual-mode contrast agent at 3.0 T (r 2/r 1 = 5.24), and is a useful T 1 contrast agent at 0.5 T (r 2/r 1 = 1.74) and 1.5 T (r 2/r 1 = 2.85). MRI studies in vivo at 3.0 T further confirm that 4-nm SPIO@PEG5k displays excellent T 1-T 2 dual-mode contrast enhancement, whereas 8-nm SPIO@PEG5k only displays T 2 contrast enhancement. CONCLUSION PEGylated SPIOs with different nanocrystal sizes and PEG coating can be used as T 1, T 2, or T 1-T 2 dual-mode contrast agents to meet the clinical demands of MRI at specific magnetic fields.
Collapse
Affiliation(s)
- Li-Hua Deng
- Medical Imaging Key Laboratory of Sichuan Province and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, People’s Republic of China
- Department of Radiology, First People’s Hospital of Neijiang, Neijiang641000, People’s Republic of China
| | - Hai Jiang
- Medical Imaging Key Laboratory of Sichuan Province and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, People’s Republic of China
| | - Fu-Lin Lu
- Medical Imaging Key Laboratory of Sichuan Province and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, People’s Republic of China
| | - Han-Wei Wang
- Medical Imaging Key Laboratory of Sichuan Province and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, People’s Republic of China
| | - Yu Pu
- Medical Imaging Key Laboratory of Sichuan Province and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, People’s Republic of China
| | - Chang-Qiang Wu
- Medical Imaging Key Laboratory of Sichuan Province and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, People’s Republic of China
| | - Hong-Jie Tang
- Department of Radiology, Nanchong Hospital of Traditional Chinese Medicine, Nanchong637000, People’s Republic of China
| | - Ye Xu
- Department of Radiology, Children’s Hospital of Chongqing Medical University, Chongqing401122, People’s Republic of China
| | - Tian-Wu Chen
- Medical Imaging Key Laboratory of Sichuan Province and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, People’s Republic of China
| | - Jiang Zhu
- Medical Imaging Key Laboratory of Sichuan Province and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, People’s Republic of China
| | - Cheng-Yi Shen
- Medical Imaging Key Laboratory of Sichuan Province and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, People’s Republic of China
| | - Xiao-Ming Zhang
- Medical Imaging Key Laboratory of Sichuan Province and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, People’s Republic of China
| |
Collapse
|
21
|
Bücker P, Richter H, Radbruch A, Sperling M, Brand M, Holling M, Van Marck V, Paulus W, Jeibmann A, Karst U. Deposition patterns of iatrogenic lanthanum and gadolinium in the human body depend on delivered chemical binding forms. J Trace Elem Med Biol 2021; 63:126665. [PMID: 33152670 DOI: 10.1016/j.jtemb.2020.126665] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Revised: 10/16/2020] [Accepted: 10/19/2020] [Indexed: 12/15/2022]
Abstract
BACKGROUND Recently, gadolinium from linear GBCAs has been reported to deposit in various regions of the body. Besides gadolinium, other lanthanides are used in medical care. In the current study, we investigated deposition of lanthanum in two patients who received lanthanum carbonate as a phosphate binder due to chronic kidney injury and compared it to additionally found Gd deposition. METHODS Tissue specimens of two patients with long-term application of lanthanum carbonate as well as possible GBCA application were investigated. Spatial distribution of gadolinium and lanthanum was determined by quantitative laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) imaging of tissue sections. The deposition of gadolinium and lanthanum in different organs was compared, and the ratio of Gd concentration to La concentration (Gd-to-La-ratio) was investigated on an individual pixel base within the images. RESULTS Deposition of Gd and La was found in all investigated tissues of both patients. Gd and La exhibited high spatial correlation for all samples, with the main deposition being located in the middle coat (tunica media) of blood vessels. The Gd-to-La-ratio was similar in the tissues investigated (between 8 ± 4 (mean ± standard deviation) and 10 ± 2), except for the thyroid vasculature and surrounding tissue (90 ± 17) as well as the cerebellum (270 ± 18). Here, the ratio was significantly increased towards higher Gd concentration. CONCLUSION The results of this study demonstrate long-term deposition of La and comparable localization of additionally found Gd in various tissues of the body. La deposition was relatively low, considering the total administered amount of lanthanum carbonate of up to 11.5 kg, indicating a low absorption and/or high excretion of lanthanum. However, the total amount of deposited La is significant and raises questions about possible adverse side effects. The ratio-approach allows for the usage of the additionally generated Gd data, without detailed knowledge about possible GBCA applications. The significantly decreased Gd-to-La-ratio in the brain might be explained by the lanthanum being released and taken up as free La3+ ion in the stomach that impedes a crossing of the blood-brain-barrier while the intravenously injected GBCAs might dechelate first when they have already crossed the blood-brain-barrier.
Collapse
Affiliation(s)
- Patrick Bücker
- Institute of Inorganic and Analytical Chemistry, University of Münster, 48149 Münster, Germany
| | - Henning Richter
- Diagnostic Imaging Research Unit (DIRU), Clinic for Diagnostic Imaging, University of Zurich, CH-8057 Zurich, Switzerland
| | - Alexander Radbruch
- Department of Diagnostic and Interventional Radiology and Neuroradiology, University Clinic Essen, University Duisburg-Essen, 45147 Essen, Germany; Department of Diagnostic and Interventional Neuroradiology, University Clinic Bonn, 53127 Bonn, Germany
| | - Michael Sperling
- Institute of Inorganic and Analytical Chemistry, University of Münster, 48149 Münster, Germany; European Virtual Institute for Speciation Analysis (EVISA), 48149 Münster, Germany
| | - Marcus Brand
- Department of Medicine D, University Hospital Münster, Division of General Internal Medicine, Nephrology and Rheumatology, 48149 Münster, Germany
| | - Markus Holling
- Department of Neurosurgery, University Hospital Münster, 48149 Münster, Germany
| | - Veerle Van Marck
- Department of Pathology, University Hospital Münster, 48149 Münster, Germany
| | - Werner Paulus
- Department of Neuropathology, University Hospital Münster, 48149 Münster, Germany
| | - Astrid Jeibmann
- Department of Neuropathology, University Hospital Münster, 48149 Münster, Germany
| | - Uwe Karst
- Institute of Inorganic and Analytical Chemistry, University of Münster, 48149 Münster, Germany.
| |
Collapse
|
22
|
Comprehensive phenotyping revealed transient startle response reduction and histopathological gadolinium localization to perineuronal nets after gadodiamide administration in rats. Sci Rep 2020; 10:22385. [PMID: 33372182 PMCID: PMC7769977 DOI: 10.1038/s41598-020-79374-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2020] [Accepted: 12/01/2020] [Indexed: 01/28/2023] Open
Abstract
Gadolinium based contrast agents (GBCAs) are widely used in clinical MRI since the mid-1980s. Recently, concerns have been raised that trace amounts of Gadolinium (Gd), detected in brains even long time after GBCA application, may cause yet unrecognized clinical consequences. We therefore assessed the behavioral phenotype, neuro-histopathology, and Gd localization after repeated administration of linear (gadodiamide) or macrocyclic (gadobutrol) GBCA in rats. While most behavioral tests revealed no difference between treatment groups, we observed a transient and reversible decrease of the startle reflex after gadodiamide application. Residual Gd in the lateral cerebellar nucleus was neither associated with a general gene expression pathway deregulation nor with neuronal cell loss, but in gadodiamide-treated rats Gd was associated with the perineuronal net protein aggrecan and segregated to high molecular weight fractions. Our behavioral finding together with Gd distribution and speciation support a substance class difference for Gd presence in the brain after GBCA application.
Collapse
|
23
|
Russell E, McMahon SJ, Russell B, Mohamud H, McGarry CK, Schettino G, Prise KM. Effects of Gadolinium MRI Contrast Agents on DNA Damage and Cell Survival when Used in Combination with Radiation. Radiat Res 2020; 194:298-309. [PMID: 32942305 DOI: 10.1667/rade-20-00008.1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Accepted: 06/23/2020] [Indexed: 11/03/2022]
Abstract
Gadolinium is a commonly used contrast agent for magnetic resonance imaging (MRI). The goal of this work was to determine how MRI contrast agents affect radiosensitivity for tumour cells. Using a 225kVp X-ray cabinet source, immunofluorescence and clonogenic assays were performed on six cancer cell lines: lung (H460), pancreas (MiaPaCa2), prostate (DU145), breast (MCF7), brain (U87) and liver (HEPG2). Dotarem® contrast agent, at concentrations of 0.2, 2 and 20 mM, was used to determine its effect on DNA damage and cell survival. Measurements were performed using inductively coupled plasma mass spectrometry (ICP-MS) to determine the amount of gadolinium taken up by each cell line for each concentration. A statistically significant increase in DNA damage was seen for all cell lines at a dose of 1 Gy for concentrations of 2 and 20 mM, at 1 h postirradiation. At 24 h postirradiation, most of the DNA damage had been repaired, with approximately 90% repair for almost all doses of radiation and concentrations of Dotarem. Clonogenic results showed no statistically significant decrease in cell survival for any cell line or concentration. Uptake measurements showed cell line-specific variations in uptake, with MCF7 and HEPG2 cells having a high percentage uptake compared to other cell lines, with 151.4 ± 0.3 × 10-15 g and 194.8 ± 0.4 × 10-15 g per cell, respectively, at 2 mM Dotarem concentration. In this work, a variability in gadolinium uptake was observed between cell lines. A significant increase was seen in initial levels of DNA damage after 1 Gy irradiation for all six cancer cell lines; however, no significant decrease in cell survival was seen with the clonogenic assay. The observation of high levels of repair suggest that while initial levels of DNA damage are increased, this damage is almost entirely repaired within 24 h, and does not affect the ability of cells to survive and produce colonies.
Collapse
Affiliation(s)
- Emily Russell
- Patrick G. Johnson Centre for Cancer Research, Queen's University Belfast, Belfast, BT9 7AE, United Kingdom.,National Physical Laboratory, Teddington, TW11 0LW, United Kingdom
| | - Stephen J McMahon
- Patrick G. Johnson Centre for Cancer Research, Queen's University Belfast, Belfast, BT9 7AE, United Kingdom
| | - Ben Russell
- National Physical Laboratory, Teddington, TW11 0LW, United Kingdom
| | - Hibaaq Mohamud
- National Physical Laboratory, Teddington, TW11 0LW, United Kingdom
| | - Conor K McGarry
- Patrick G. Johnson Centre for Cancer Research, Queen's University Belfast, Belfast, BT9 7AE, United Kingdom.,Radiotherapy Physics, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, United Kingdom
| | - Giuseppe Schettino
- National Physical Laboratory, Teddington, TW11 0LW, United Kingdom.,University of Surrey, Department of Physics, Guilford, GU2 7XH, United Kingdom
| | - Kevin M Prise
- Patrick G. Johnson Centre for Cancer Research, Queen's University Belfast, Belfast, BT9 7AE, United Kingdom
| |
Collapse
|
24
|
Piera-Velazquez S, Wermuth PJ, Gomez-Reino JJ, Varga J, Jimenez SA. Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis. Semin Arthritis Rheum 2020; 50:1226-1237. [PMID: 33059296 DOI: 10.1016/j.semarthrit.2020.09.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 08/19/2020] [Accepted: 09/09/2020] [Indexed: 01/19/2023]
Abstract
Numerous drugs and chemical substances are capable of inducing exaggerated tissue fibrotic responses. The vast majority of these agents cause localized fibrotic tissue reactions or fibrosis confined to specific organs. Although much less frequent, chemically-induced systemic fibrotic disorders have been described, sometimes occurring as temporally confined outbreaks. These include the Toxic Oil Syndrome (TOS), the Eosinophilia-Myalgia Syndrome (EMS), and Nephrogenic Systemic Fibrosis (NSF). Although each of these disorders displays some unique characteristics, they all share crucial features with Systemic Sclerosis (SSc), the prototypic idiopathic systemic fibrotic disease, including vasculopathy, chronic inflammatory cell infiltration of affected tissues, and cutaneous and visceral tissue fibrosis. The study of the mechanisms and molecular alterations involved in the development of the chemically-induced systemic fibrotic disorders has provided valuable clues that may allow elucidation of SSc etiology and pathogenesis. Here, we review relevant aspects of the TOS, EMS, and NSF epidemic outbreaks of chemically-induced systemic fibrosing disorders that provide strong support to the hypothesis that SSc is caused by a toxic or biological agent that following its internalization by endothelial cells induces in genetically predisposed individuals a series of molecular alterations that result in the development of SSc clinical and pathological alterations.
Collapse
Affiliation(s)
- Sonsoles Piera-Velazquez
- Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, United States
| | - Peter J Wermuth
- Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, United States
| | - Juan J Gomez-Reino
- Fundacion IDIS, Instituto de Investigacion Sanitaria, Hospital Clinico Universitario, Santiago de Compostela, Spain
| | - John Varga
- Rheumatology Division, North Western Scleroderma Program, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
| | - Sergio A Jimenez
- Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, United States
| |
Collapse
|
25
|
Anterior pituitary gland T1 signal intensity is influenced by time delay after injection of gadodiamide. Sci Rep 2020; 10:14967. [PMID: 32917963 PMCID: PMC7486291 DOI: 10.1038/s41598-020-71981-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Accepted: 08/20/2020] [Indexed: 01/01/2023] Open
Abstract
To test the hypothesis of washout from the anterior pituitary (AP) gland after serial injections of gadodiamide. We included 59 patients with history of at least 5 injections of gadodiamide. Values of mean signal intensity of the AP and of the central pons were measured on unenhanced sagittal T1-weighted images. AP-to-pons signal intensity ratios were calculated dividing the values of the AP by those of the pons. The measurements were performed using MR images acquired at four different time points including baseline (prior to any gadodiamide injection), minimum post-injection time delay, maximum post-injection time delay, and last available MR scans. Normalized ratios (i.e. ratios divided total volume of injected gadodiamide) were also calculated. To assess the difference between ratios, non-parametric Wilcoxon signed-rank test was applied. The correlations were tested with non-parametric Spearman correlation coefficient. A p-value < 0.05 was considered as statistically significant. A statistically significant increase of AP signal intensity was found by comparing the baseline scans with both the minimum time delay (p = 0.003) and maximum time delay scans (p = 0.005). We found significant higher normalized ratios for minimum post-injection time delay with respect to maximum post-injection time delay (p < 0.001). The normalized ratios demonstrated a statistically significant negative correlation with the post-injection time delay (r = − 0.31; p = 0.006). The findings of this study suggest that washout phenomena of retained/deposited gadolinium from the AP are influenced by the total injected volume and post-injection time delay.
Collapse
|
26
|
Wu C, Chen T, Deng L, Xia Q, Chen C, Lan M, Pu Y, Tang H, Xu Y, Zhu J, Xu C, Shen C, Zhang X. Mn(ii) chelate-coated superparamagnetic iron oxide nanocrystals as high-efficiency magnetic resonance imaging contrast agents. NANOSCALE ADVANCES 2020; 2:2752-2757. [PMID: 36132378 PMCID: PMC9416939 DOI: 10.1039/d0na00117a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/12/2020] [Accepted: 06/15/2020] [Indexed: 06/15/2023]
Abstract
In this communication, a paramagnetic bifunctional manganese(ii) chelate ([Mn(Dopa-EDTA)]2-) containing a catechol group is designed and synthesized. The catechol can bind iron ions on the surface of superparamagnetic iron oxide (SPIO) nanocrystals to form core-shell nanoparticles. Both 4 and 7 nm SPIO@[Mn(Dopa-EDTA)]2- show good water solubility, single-crystal dispersion, and low cytotoxicity. The study of the interplay between the longitudinal and transverse relaxation revealed that 4 nm SPIO@[Mn(Dopa-EDTA)]2- with lower r 2/r 1 = 1.75 at 0.5 T tends to be a perfect T 1 contrast agent while 7 nm SPIO@[Mn(Dopa-EDTA)]2- with a higher r 2/r 1 = 15.0 at 3.0 T tends to be a T 2 contrast agent. Interestingly, 4 nm SPIO@[Mn(Dopa-EDTA)]2- with an intermediate value of r 2/r 1 = 5.26 at 3.0 T could act as T 1-T 2 dual-modal contrast agent. In vivo imaging with the 4 nm SPIO@[Mn(Dopa-EDTA)]2- nanoparticle shows unique imaging features: (1) long-acting vascular imaging and different signal intensity changes between the liver parenchyma and blood vessels with the CEMRA sequence; (2) the synergistic contrast enhancement of hepatic imaging with the T 1WI and T 2WI sequence. In summary, these Fe/Mn hybrid core-shell nanoparticles, with their ease of synthesis, good biocompatibility, and synergistic contrast enhancement ability, may provide a useful method for tissue and vascular MR imaging.
Collapse
Affiliation(s)
- Changqiang Wu
- Sichuan Key Laboratory of Medical Imaging and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College Nanchong 637000 China
| | - Tianwu Chen
- Sichuan Key Laboratory of Medical Imaging and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College Nanchong 637000 China
| | - Lihua Deng
- Sichuan Key Laboratory of Medical Imaging and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College Nanchong 637000 China
- Department of Radiology, First People's Hospital of Neijiang Neijiang 641000 China
| | - Qian Xia
- Sichuan Key Laboratory of Medical Imaging and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College Nanchong 637000 China
| | - Chuan Chen
- School of Pharmacy, North Sichuan Medical College Nanchong 637000 China
| | - Mu Lan
- Sichuan Key Laboratory of Medical Imaging and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College Nanchong 637000 China
| | - Yu Pu
- Sichuan Key Laboratory of Medical Imaging and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College Nanchong 637000 China
| | - Hongjie Tang
- Department of Radiology, Nanchong Hospital of Traditional Chinese Medicine Nanchong 637000 China
| | - Ye Xu
- Department of Radiology, Children's Hospital of Chongqing Medical University Chongqing 401122 China
| | - Jiang Zhu
- Sichuan Key Laboratory of Medical Imaging and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College Nanchong 637000 China
- School of Pharmacy, North Sichuan Medical College Nanchong 637000 China
| | - Chenjie Xu
- School of Chemical and Biomedical Engineering, Nanyang Technological University Singapore
| | - Chengyi Shen
- Sichuan Key Laboratory of Medical Imaging and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College Nanchong 637000 China
| | - Xiaoming Zhang
- Sichuan Key Laboratory of Medical Imaging and School of Medical Imaging, Affiliated Hospital of North Sichuan Medical College Nanchong 637000 China
| |
Collapse
|
27
|
Mallio CA, Parillo M, Zobel BB, Parizel PM, Quattrocchi CC. Effect of Exposure to Gadodiamide and Brain Irradiation on
T
1
‐Weighted Images and
ADC
Maps of the Dentate Nucleus. J Magn Reson Imaging 2020; 52:1525-1530. [DOI: 10.1002/jmri.27198] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2020] [Revised: 05/02/2020] [Accepted: 05/05/2020] [Indexed: 12/24/2022] Open
Affiliation(s)
- Carlo A. Mallio
- Departmental Faculty of Medicine and Surgery Università Campus Bio‐Medico di Roma Rome Italy
| | - Marco Parillo
- Departmental Faculty of Medicine and Surgery Università Campus Bio‐Medico di Roma Rome Italy
| | - Bruno Beomonte Zobel
- Departmental Faculty of Medicine and Surgery Università Campus Bio‐Medico di Roma Rome Italy
| | - Paul M. Parizel
- Department of Radiology Antwerp University Hospital Edegem Belgium
| | - Carlo C. Quattrocchi
- Departmental Faculty of Medicine and Surgery Università Campus Bio‐Medico di Roma Rome Italy
| |
Collapse
|
28
|
Mallio CA, Quattrocchi CC, Rovira À, Parizel PM. Gadolinium Deposition Safety: Seeking the Patient's Perspective. AJNR Am J Neuroradiol 2020; 41:944-946. [PMID: 32381539 DOI: 10.3174/ajnr.a6586] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
29
|
Patil R, Galstyan A, Grodzinski ZB, Shatalova ES, Wagner S, Israel LL, Ding H, Black KL, Ljubimova JY, Holler E. Single- and Multi-Arm Gadolinium MRI Contrast Agents for Targeted Imaging of Glioblastoma. Int J Nanomedicine 2020; 15:3057-3070. [PMID: 32431501 PMCID: PMC7200230 DOI: 10.2147/ijn.s238265] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Accepted: 02/25/2020] [Indexed: 12/22/2022] Open
Abstract
Background Position of gadolinium atom(s) plays a key role in contrast enhancement of gadolinium-based contrast agents. To gain a better understanding of effects of distance of gadolinium in relation to the nanoconjugate platform, we designed and synthesized single- and multi-arm (“star”) gadolinium conjugates equipped with antibody and peptides for targeting. The contrast agents were studied for their tumor imaging performance in a glioma mouse model. Materials and Methods Antibody- and peptide-targeted nano contrast agents (NCAs) were synthesized using polymalic acid platforms of different sizes. Gadolinium-DOTA and intermediates were attached as amides and targeting agents such as antibodies and peptides as thioethers. For in vivo experiments, we used human U87MG xenografts as glioma models. Magnetic resonance imaging (MRI) was performed on a Bruker BioSpec 94/20USR 9.4 T small-animal scanner. Delivery of contrast agents across the blood–brain barrier was studied by fluorescent microscopy. Results All contrast agents accumulated into tumor and showed composition-dependent imaging performance. Peptide-targeted mini-NCAs had hydrodynamic diameters in the range 5.2–9.4 nm and antibody-targeted NCAs had diameters in the range 15.8–20.5 nm. Zeta potentials were in the range of –5.4–−8.2 mV and −4.6–−8.8 mV, respectively. NCAs showed superior relaxivities compared to MultiHance at 9.4 T. The signal enhancement indicated maximum accumulation in tumor 30–60 minutes after intravenous injection of the mouse tail vein. Only targeted NCAs were retained in tumor for up to 3 hours and displayed contrast enhancement. Conclusion The novel targeted NCAs with star-PEG features displayed improved relaxivity and greater contrast compared with commercial MultiHance contrast agent. The enhancement by mini-NCAs showed clearance of tumor contrast after 3 hours providing a suitable time window for tumor diagnosis in clinics. The technology provides a great tool with the promise of differential MRI diagnosis of brain tumors.
Collapse
Affiliation(s)
- Rameshwar Patil
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Anna Galstyan
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Zachary B Grodzinski
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Ekaterina S Shatalova
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Shawn Wagner
- Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Liron L Israel
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Hui Ding
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Keith L Black
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Julia Y Ljubimova
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.,Oncology Translational Program, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Eggehard Holler
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| |
Collapse
|
30
|
Nörenberg D, Schmidt F, Schinke K, Frenzel T, Pietsch H, Giese A, Ertl-Wagner B, Levin J. Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice. PLoS One 2020; 15:e0231495. [PMID: 32324769 PMCID: PMC7179865 DOI: 10.1371/journal.pone.0231495] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2019] [Accepted: 03/24/2020] [Indexed: 11/22/2022] Open
Abstract
Objectives To examine potential gadolinium (Gd) accumulation in the brain of healthy mice after long-term oral administration of Gd-containing food pellets and to investigate whether Gd leads to adverse central nervous system (CNS) effects, specifically focussing on locomotor impairment in Gd exposed compared to control animals. Materials and methods The local Animal Experimental Ethics Committee approved all procedures and applications. Fifteen female C57Bl/6 mice were orally exposed to a daily intake of 0.57 mmol Gd chloride/ kg body weight over a period of 90 weeks from the age of 4 weeks on. Gd-free, but otherwise equivalent experimental diets were given to the control group (N = 13). The animals were monitored daily by animal caretakers regarding any visible signs of distress and evaluated clinically every four weeks for the first 60 weeks and afterwards every two weeks for a better temporal resolution of potential long-term effects regarding impairment of motor performance and loss of body weight. The individual Gd content was measured using mass spectrometry in a sub-cohort of N = 6 mice. Results The absolute brain Gd levels of the Gd-exposed mice were significantly increased compared to control mice (0.033± 0.009 vs. 0.006± 0.002 nmol Gd/ g brain tissue). Long-term oral Gd exposure over almost the entire life-span did not lead to adverse CNS effects including locomotor changes (rotarod performance, p = 0.1467) in healthy mice throughout the study period. Gd-exposed mice showed less increased body weight compared to control mice during the study period (p = 0.0423). Histopathological alterations, such as hepatocellular vacuolization due to fatty change in the liver and a loss of nucleated cells in the red pulp of the spleen, were found in peripheral organs of both groups. Conclusions Low levels of intracerebral Gd caused by chronic oral exposure over almost the entire life span of mice did not lead to alterations in locomotor abilities in healthy mice throughout the normal aging process.
Collapse
Affiliation(s)
- Dominik Nörenberg
- Department of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Mannheim, Germany
- Department of Radiology, Munich University Hospitals, LMU, Munich, Germany
- * E-mail:
| | - Felix Schmidt
- Munich Center for Neuropathology, Ludwig-Maximilians-University Munich, Munich, Germany
- Department of Neurology, Munich University Hospitals, LMU, Munich, Germany
| | - Karin Schinke
- Munich Center for Neuropathology, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Thomas Frenzel
- MR and CT Contrast Media Research, Bayer AG, Berlin, Germany
| | | | - Armin Giese
- Munich Center for Neuropathology, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Birgit Ertl-Wagner
- Department of Radiology, Munich University Hospitals, LMU, Munich, Germany
- Department of Medical Imaging, The Hospital for Sick Children, University of Toronto, Toronto, Canada
| | - Johannes Levin
- Department of Neurology, Munich University Hospitals, LMU, Munich, Germany
- German Center of Neurodegenerative Diseases (DZNE), Munich, Germany
| |
Collapse
|
31
|
Mallio CA, Rovira À, Parizel PM, Quattrocchi CC. Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies. Neuroradiology 2020; 62:925-934. [DOI: 10.1007/s00234-020-02434-8] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Accepted: 04/08/2020] [Indexed: 02/06/2023]
|
32
|
Rasschaert M, Weller RO, Schroeder JA, Brochhausen C, Idée JM. Retention of Gadolinium in Brain Parenchyma: Pathways for Speciation, Access, and Distribution. A Critical Review. J Magn Reson Imaging 2020; 52:1293-1305. [PMID: 32246802 PMCID: PMC7687192 DOI: 10.1002/jmri.27124] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Revised: 02/05/2020] [Accepted: 02/06/2020] [Indexed: 12/21/2022] Open
Abstract
The unexpected appearance of T1 hyperintensities, mostly in the dentate nucleus and the globus pallidus, during nonenhanced MRI was reported in 2014. This effect is associated with prior repeated administrations of gadolinium (Gd)‐based contrast agents (GBCAs) in patients with a functional blood–brain barrier (BBB). It is widely assumed that GBCAs do not cross the intact BBB, but the observation of these hypersignals raises questions regarding this assumption. This review critically discusses the mechanisms of Gd accumulation in the brain with regard to access pathways, Gd species, tissue distribution, and subcellular location. We propose the hypothesis that there is early access of Gd species to cerebrospinal fluid, followed by passive diffusion into the brain parenchyma close to the cerebral ventricles. When accessing areas rich in endogenous metals or phosphorus, the less kinetically stable GBCAs would dissociate, and Gd would bind to endogenous macromolecules, and/or precipitate within the brain tissue. It is also proposed that Gd species enter the brain parenchyma along penetrating cortical arteries in periarterial pial‐glial basement membranes and leave the brain along intramural peri‐arterial drainage (IPAD) pathways. Lastly, Gd/GBCAs may access the brain parenchyma directly from the blood through the BBB in the walls of capillaries. It is crucial to distinguish between the physiological distribution and drainage pathways for GBCAs and the possible dissociation of less thermodynamically/kinetically stable GBCAs that lead to long‐term Gd deposition in the brain. Level of Evidence 5. Technical Efficacy Stage 3.
Collapse
Affiliation(s)
| | - Roy O Weller
- Neuropathology, Faculty of Medicine University of Southampton, Southampton General Hospital, Southampton, UK
| | - Josef A Schroeder
- Institute of Pathology, University of Regensburg, Regensburg, Germany
| | | | - Jean-Marc Idée
- Guerbet, Research and Innovation Division, Aulnay-sous-Bois, France
| |
Collapse
|
33
|
Minaeva O, Hua N, Franz ES, Lupoli N, Mian AZ, Farris CW, Hildebrandt AM, Kiernan PT, Evers LE, Griffin AD, Liu X, Chancellor SE, Babcock KJ, Moncaster JA, Jara H, Alvarez VE, Huber BR, Guermazi A, Latour LL, McKee AC, Soto JA, Anderson SW, Goldstein LE. Nonhomogeneous Gadolinium Retention in the Cerebral Cortex after Intravenous Administration of Gadolinium-based Contrast Agent in Rats and Humans. Radiology 2019; 294:377-385. [PMID: 31769744 DOI: 10.1148/radiol.2019190461] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Background Gadolinium retention after repeated gadolinium-based contrast agent (GBCA) exposure has been reported in subcortical gray matter. However, gadolinium retention in the cerebral cortex has not been systematically investigated. Purpose To determine whether and where gadolinium is retained in rat and human cerebral cortex. Materials and Methods The cerebral cortex in Sprague-Dawley rats treated with gadopentetate dimeglumine (three doses over 4 weeks; cumulative gadolinium dose, 7.2 mmol per kilogram of body weight; n = 6) or saline (n = 6) was examined with antemortem MRI. Two human donors with repeated GBCA exposure (three and 15 doses; 1 and 5 months after exposure), including gadopentetate dimeglumine, and two GBCA-naive donors were also evaluated. Elemental brain maps (gadolinium, phosphorus, zinc, copper, iron) for rat and human brains were constructed by using laser ablation inductively coupled plasma mass spectrometry. Results Gadopentetate dimeglumine-treated rats showed region-, subregion-, and layer-specific gadolinium retention in the neocortex (anterior cingulate cortex: mean gadolinium concentration, 0.28 µg ∙ g-1 ± 0.04 [standard error of the mean]) that was comparable (P > .05) to retention in the allocortex (mean gadolinium concentration, 0.33 µg ∙ g-1 ± 0.04 in piriform cortex, 0.24 µg ∙ g-1 ± 0.04 in dentate gyrus, 0.17 µg ∙ g-1 ± 0.04 in hippocampus) and subcortical structures (0.47 µg ∙ g-1 ± 0.10 in facial nucleus, 0.39 µg ∙ g-1 ± 0.10 in choroid plexus, 0.29 µg ∙ g-1 ± 0.05 in caudate-putamen, 0.26 µg ∙ g-1 ± 0.05 in reticular nucleus of the thalamus, 0.24 µg ∙ g-1 ± 0.04 in vestibular nucleus) and significantly greater than that in the cerebellum (0.17 µg ∙ g-1 ± 0.03, P = .01) and white matter tracts (anterior commissure: 0.05 µg ∙ g-1 ± 0.01, P = .002; corpus callosum: 0.05 µg ∙ g-1 ± 0.02, P = .001; cranial nerve: 0.02 µg ∙ g-1 ± 0.01, P = .004). Retained gadolinium colocalized with parenchymal iron. T1-weighted MRI signal intensification was not observed. Gadolinium retention was detected in the cerebral cortex, pia mater, and pia-ensheathed leptomeningeal vessels in two GBCA-exposed human brains but not in two GBCA-naive human brains. Conclusion Repeated gadopentetate dimeglumine exposure is associated with gadolinium retention in specific regions, subregions, and layers of cerebral cortex that are critical for higher cognition, affect, and behavior regulation, sensorimotor coordination, and executive function. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Kanal in this issue.
Collapse
Affiliation(s)
- Olga Minaeva
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Ning Hua
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Erich S Franz
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Nicola Lupoli
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Asim Z Mian
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Chad W Farris
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Audrey M Hildebrandt
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Patrick T Kiernan
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Laney E Evers
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Allison D Griffin
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Xiuping Liu
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Sarah E Chancellor
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Katharine J Babcock
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Juliet A Moncaster
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Hernan Jara
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Victor E Alvarez
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Bertrand R Huber
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Ali Guermazi
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Lawrence L Latour
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Ann C McKee
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Jorge A Soto
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Stephan W Anderson
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| | - Lee E Goldstein
- From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass
| |
Collapse
|
34
|
|
35
|
Schöckel L, Balzer T, Pietsch H. [Increased signal intensities and gadolinium levels in the brain after administration of gadolinium-based MR contrast agents : Clinical observations and results from preclinical research]. Radiologe 2019; 59:359-368. [PMID: 30887087 DOI: 10.1007/s00117-019-0511-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
BACKGROUND Numerous clinical MRI studies have been published that describe an association between the repeated administration of (linear) gadolinium-based contrast agents and increased signal intensity in certain brain areas. In November 2017, the European Commission suspended the use of some of these contrast agents. OBJECTIVES The background for this decision, both regulatory and scientific, are presented and discussed. MATERIALS AND METHODS The regulatory decisions are evaluated and the clinical and preclinical literature is discussed. RESULTS Differences in the structure and stability of gadolinium-based contrast agent molecules explain the observed increased signal intensities in individual brain regions (e. g. dentate nucleus) after administration of multiple doses of linear contrast agents. This phenomenon was not observed after administration of multiple doses of macrocyclic contrast agents. Preclinical studies have confirmed these results. CONCLUSION To date, no clinical symptoms have been confirmed to be associated with the increased signal intensity or gadolinium presence in the brain.
Collapse
Affiliation(s)
- L Schöckel
- Pharmaceuticals Division, Medical & Clinical Affairs Radiology, Bayer AG, Berlin, Deutschland
| | - T Balzer
- Pharmaceuticals, Medical & Clinical Affairs Radiology, Bayer U.S. LLC, 100 Bayer Boulevard, 07981, Whippany, NJ, USA.
| | - H Pietsch
- Research & Development, Pharmaceuticals, MR and CT Contrast Media Research, Bayer AG, Berlin, Deutschland
| |
Collapse
|
36
|
Kiviniemi A, Gardberg M, Ek P, Frantzén J, Bobacka J, Minn H. Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents. Neuroradiology 2019; 61:535-544. [DOI: 10.1007/s00234-019-02172-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Accepted: 01/16/2019] [Indexed: 10/27/2022]
|
37
|
KUBOTA AYANO, MATSUKAWA TAKEHISA, YANAGIE HIRONOBU, YANAGAWA MASASHI, HIRATA TAKAFUMI, SHINOHARA ATSUKO, YOKOYAMA KAZUHITO. Quantitative Bio-imaging of Gadolinium-157 in Tissues Through Laser-ablation ICP-MS for Neutron Capture Therapy. JUNTENDO IJI ZASSHI 2019. [DOI: 10.14789/jmj.2019.65.jmj19-oa12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- AYANO KUBOTA
- Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine
| | - TAKEHISA MATSUKAWA
- Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine
- Department of Forensic Medicine, Juntendo University Faculty of Medicine
| | - HIRONOBU YANAGIE
- Department of Nuclear Engineering and Management, The University of Tokyo
| | - MASASHI YANAGAWA
- Department of Veterinary Medicine, Obihiro University of Agriculture and Veterinary Medicine
| | | | - ATSUKO SHINOHARA
- Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine
- Research Institute for Cultural Studies, Seisen University
| | - KAZUHITO YOKOYAMA
- Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine
- Department of Epidemiology and Social Medicine, International University of Health and Welfare Graduate School of Public Health
| |
Collapse
|
38
|
Clases D, Fingerhut S, Jeibmann A, Sperling M, Doble P, Karst U. LA-ICP-MS/MS improves limits of detection in elemental bioimaging of gadolinium deposition originating from MRI contrast agents in skin and brain tissues. J Trace Elem Med Biol 2019; 51:212-218. [PMID: 30466933 DOI: 10.1016/j.jtemb.2018.10.021] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 09/18/2018] [Accepted: 10/29/2018] [Indexed: 10/28/2022]
Abstract
A novel analytical method to detect the retention of gadolinium from contrast agents for magnetic resonance imaging (MRI) in tissue samples of patients is presented. It is based on laser ablation - inductively coupled plasma - triple quadrupole - mass spectrometry (LA-ICP-MS/MS). Both Gd and P were monitored with a mass shift of +16, corresponding to mono-oxygenated species, as well as Zn, Ca, and Fe on-mass. This method resulted in a significantly reduced background and improved limits of detection not only for phosphorus, but also for gadolinium. These improvements were essential to perform elemental bioimaging with improved resolution of 5 μm x 5 μm, allowing the detection of small Gd deposits in fibrotic skin and brain tumour tissue with diameters of approximately 50 μm. Detailed analyses of these regions revealed that most Gd was accompanied with P and Ca, indicating co-precipitation.
Collapse
Affiliation(s)
- David Clases
- University of Münster, Institute of Inorganic and Analytical Chemistry, Corrensstr. 30, 48149, Münster, Germany; Elemental Bioimaging Facility, University of Technology Sydney, Broadway, 2007, NSW, Australia
| | - Stefanie Fingerhut
- University of Münster, Institute of Inorganic and Analytical Chemistry, Corrensstr. 30, 48149, Münster, Germany
| | - Astrid Jeibmann
- University Hospital Münster, Institute of Neuropathology, Pottkamp 2, 48149, Münster, Germany
| | - Michael Sperling
- University of Münster, Institute of Inorganic and Analytical Chemistry, Corrensstr. 30, 48149, Münster, Germany; European Virtual Institute for Speciation Analysis (EVISA), Mendelstraße 11, 48149, Münster, Germany
| | - Philip Doble
- Elemental Bioimaging Facility, University of Technology Sydney, Broadway, 2007, NSW, Australia
| | - Uwe Karst
- University of Münster, Institute of Inorganic and Analytical Chemistry, Corrensstr. 30, 48149, Münster, Germany.
| |
Collapse
|
39
|
Gianolio E, Gregorio ED, Aime S. Chemical Insights into the Issues of Gd Retention in the Brain and Other Tissues Upon the Administration of Gd-Containing MRI Contrast Agents. Eur J Inorg Chem 2018. [DOI: 10.1002/ejic.201801220] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Eliana Gianolio
- Dipartimento di Biotecnologie Molecolari e Scienze per la Salute; Centro di Imaging molecolare; Università degli Studi di Torino; Via Nizza 52 10126 Torino Italy
| | - Enza Di Gregorio
- Dipartimento di Biotecnologie Molecolari e Scienze per la Salute; Centro di Imaging molecolare; Università degli Studi di Torino; Via Nizza 52 10126 Torino Italy
| | - Silvio Aime
- Dipartimento di Biotecnologie Molecolari e Scienze per la Salute; Centro di Imaging molecolare; Università degli Studi di Torino; Via Nizza 52 10126 Torino Italy
| |
Collapse
|
40
|
Mori V, Sawicki LM, Sewerin P, Eichner M, Schaarschmidt BM, Oezel L, Gehrmann S, Bittersohl B, Antoch G, Schleich C. Differences of radiocarpal cartilage alterations in arthritis and osteoarthritis using morphological and biochemical magnetic resonance imaging without gadolinium-based contrast agent administration. Eur Radiol 2018; 29:2581-2588. [PMID: 30542752 DOI: 10.1007/s00330-018-5880-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 10/19/2018] [Accepted: 11/08/2018] [Indexed: 11/29/2022]
Abstract
OBJECTIVES To identify differences of radiocarpal cartilage alterations in osteoarthritis and arthritis using multiparametrical magnetic resonance imaging (MRI) comprising morphological and biochemical sequences without gadolinium-based contrast agent administration. METHODS In this prospective study, multiparametrical MRI of the radiocarpal cartilage was performed in 47 participants (mean age, 46.6 ± 17.6 years; min., 20 years; max., 79 years) on a 3 Tesla MRI. The cohort consisted of 11 patients suffering from arthritis, 10 patients with osteoarthritis, 14 patients after distal radius fracture, and 12 healthy volunteers. The radiocarpal cartilage was assessed using morphological (DESS, TrueFISP) and biochemical (T2*) MRI sequences without the application of intravenous contrast agent. The modified Outerbridge classification system for morphological and region-of-interest analyses for biochemical analysis was applied to assess the degree of cartilage damage in each patient before data were statistically tested for significant difference between the groups using a post hoc Tukey test. RESULTS In morphological imaging, cartilage damage was significantly more frequent in arthritis and osteoarthritis than in healthy volunteers (DESS: p = 0.01, p = 0.0004; TrueFISP: p = 0.02, p = 0.0001). In T2* imaging, patients with osteoarthritis showed higher cartilage damage compared to patients with arthritis (p = 0.01). CONCLUSION With multiparametrical MRI, it is possible to identify differences of radiocarpal cartilage alterations of patients with arthritis and osteoarthritis using the combination of morphological and biochemical MR imaging of the radiocarpal cartilage without the application of contrast agent. Multiparametrical MRI without the usage of contrast agent may be a potential tool helping to distinguish both entities. KEY POINTS • Multiparametrical MRI with morphological and biochemical sequences allows the differentiation of patients with arthritis and osteoarthritis. • High-resolution MRI of radiocarpal cartilage is possible without administration of contrast agent.
Collapse
Affiliation(s)
- Valentina Mori
- Department of Diagnostic and Interventional Radiology, Medical Faculty, University of Düsseldorf, 40225, Düsseldorf, Germany
| | - Lino M Sawicki
- Department of Diagnostic and Interventional Radiology, Medical Faculty, University of Düsseldorf, 40225, Düsseldorf, Germany.
| | - Philipp Sewerin
- Department and Hiller-Research-Unit for Rheumatology, UKD, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Markus Eichner
- Department of Diagnostic and Interventional Radiology, Medical Faculty, University of Düsseldorf, 40225, Düsseldorf, Germany
| | - Benedikt M Schaarschmidt
- Department of Diagnostic and Interventional Radiology, Medical Faculty, University of Düsseldorf, 40225, Düsseldorf, Germany
| | - Lisa Oezel
- Department of Trauma and Hand Surgery, University Hospital, Moorenstrasse 5, 40225, Düsseldorf, Germany
| | - Sebastian Gehrmann
- Department of Trauma and Hand Surgery, University Hospital, Moorenstrasse 5, 40225, Düsseldorf, Germany
| | - Bernd Bittersohl
- Department of Orthopedics, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany
| | - Gerald Antoch
- Department of Diagnostic and Interventional Radiology, Medical Faculty, University of Düsseldorf, 40225, Düsseldorf, Germany
| | - Christoph Schleich
- Department of Diagnostic and Interventional Radiology, Medical Faculty, University of Düsseldorf, 40225, Düsseldorf, Germany
| |
Collapse
|
41
|
Bloem JL, Reijnierse M, Huizinga TWJ, van der Helm-van Mil AHM. MR signal intensity: staying on the bright side in MR image interpretation. RMD Open 2018; 4:e000728. [PMID: 29955387 PMCID: PMC6018882 DOI: 10.1136/rmdopen-2018-000728] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Revised: 06/07/2018] [Accepted: 06/11/2018] [Indexed: 12/21/2022] Open
Abstract
In 2003, the Nobel Prize for Medicine was awarded for contribution to the invention of MRI, reflecting the incredible value of MRI for medicine. Since 2003, enormous technical advancements have been made in acquiring MR images. However, MRI has a complicated, accident-prone dark side; images are not calibrated and respective images are dependent on all kinds of subjective choices in the settings of the machine, acquisition technique parameters, reconstruction techniques, data transmission, filtering and postprocessing techniques. The bright side is that understanding MR techniques increases opportunities to unravel characteristics of tissue. In this viewpoint, we summarise the different subjective choices that can be made to generate MR images and stress the importance of communication between radiologists and rheumatologists to correctly interpret images.
Collapse
Affiliation(s)
- Johan L Bloem
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Monique Reijnierse
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Tom W J Huizinga
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
| | | |
Collapse
|